<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.2 20190208//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?><?SourceDTD.Version 1.2?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Biomol Struct Dyn</journal-id><journal-id journal-id-type="iso-abbrev">J Biomol Struct Dyn</journal-id><journal-title-group><journal-title>Journal of Biomolecular Structure &#x00026; Dynamics</journal-title></journal-title-group><issn pub-type="ppub">0739-1102</issn><issn pub-type="epub">1538-0254</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7651333</article-id><article-id pub-id-type="pmid">33150860</article-id><article-id pub-id-type="doi">10.1080/07391102.2020.1842246</article-id><article-id pub-id-type="publisher-id">1842246</article-id><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version><article-categories><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Traditional medicinal plants against replication, maturation and transmission targets of SARS-CoV-2: computational investigation</article-title><alt-title alt-title-type="left-running-head">P. Mondal et al.</alt-title><alt-title alt-title-type="right-running-head">Journal of Biomolecular Structure and Dynamics</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mondal</surname><given-names>Priya</given-names></name><xref ref-type="aff" rid="AF0001">a</xref><xref ref-type="aff" rid="AF0002">b</xref><xref ref-type="author-notes" rid="FN0001">*</xref><xref ref-type="corresp" rid="AN0001"/></contrib><contrib contrib-type="author"><name><surname>Natesh</surname><given-names>Jagadish</given-names></name><xref ref-type="aff" rid="AF0001">a</xref><xref ref-type="aff" rid="AF0002">b</xref><xref ref-type="author-notes" rid="FN0001">*</xref><xref ref-type="corresp" rid="AN0001"/></contrib><contrib contrib-type="author"><name><surname>Abdul Salam</surname><given-names>Abdul Ajees</given-names></name><xref ref-type="aff" rid="AF0003">c</xref></contrib><contrib contrib-type="author"><name><surname>Thiyagarajan</surname><given-names>Saravanamuthu</given-names></name><xref ref-type="aff" rid="AF0004">d</xref></contrib><contrib contrib-type="author"><name><surname>Meeran</surname><given-names>Syed Musthapa</given-names></name><xref ref-type="aff" rid="AF0001">a</xref><xref ref-type="aff" rid="AF0002">b</xref></contrib><aff id="AF0001"><label>a</label><institution>Department of Biochemistry, CSIR-Central Food Technological Research Institute</institution>, <city>Mysore</city>, <state>Karnataka</state>, <country>India</country></aff><aff id="AF0002"><label>b</label><institution>Academy of Scientific and Innovative Research (AcSIR)</institution>, <city>Ghaziabad</city>, <state>Uttar Pradesh</state>, <country>India</country></aff><aff id="AF0003"><label>c</label><institution>Department of Atomic and Molecular Physics, Centre for Applied Nanosciences, Manipal Academy of Higher Education</institution>, <city>Manipal</city>, <state>Karnataka</state>, <country>India</country></aff><aff id="AF0004"><label>d</label><institution>Institute of Bioinformatics and Applied Biotechnology (IBAB), Biotech Park, Electronic City Phase I</institution>, <city>Electronic City, Bangalore</city>, <state>Karnataka</state>, <country>India</country></aff></contrib-group><author-notes><fn id="FN0001"><label>*</label><p>Equal contributors.</p></fn><fn id="AUFN3"><p>Supplemental data for this article can be accessed online at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/07391102.2020.1842246">https://doi.org/10.1080/07391102.2020.1842246</ext-link>.</p></fn><corresp id="AN0001"><bold>CONTACT</bold> Syed Musthapa Meeran <email>s.musthapa@cftri.res.in</email><institution>Laboratory of Cancer Epigenetics, Department of Biochemistry, CSIR-Central Food Technological Research Institute (CSIR-CFTRI)</institution>, <city>Mysore</city>, <state>Karnataka</state><postal-code>570020</postal-code>, <country>India</country>; Abdul Ajees Abdul Salam <email>abdul.ajees@manipal.edu</email><institution>Department of Atomic and Molecular Physics, Centre for Applied Nanosciences, Manipal Academy of Higher Education</institution>, <postal-code>Manipal-576104</postal-code>, <state>Karnataka</state>, <country>India</country>.</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>5</day><month>11</month><year>2020</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2020</year></pub-date><fpage seq="1">1</fpage><lpage>18</lpage><permissions><copyright-statement>&#x000a9; 2020 Informa UK Limited, trading as Taylor &#x00026; Francis Group</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Informa UK Limited, trading as Taylor &#x00026; Francis Group</copyright-holder><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="TBSD_0_1842246.pdf"/><abstract><title>Abstract</title><p>COVID-19 is an infectious pandemic caused by the SARS-CoV-2 virus. The critical components of SARS-CoV-2 are the spike protein (S-protein) and the main protease (M<sup>pro</sup>). M<sup>pro</sup> is required for the maturation of the various polyproteins involved in replication and transcription. S-protein helps the SARS-CoV-2 to enter the host cells through the angiotensin-converting enzyme 2 (ACE2). Since ACE2 is required for the binding of SARS-CoV-2 on the host cells, ACE2 inhibitors and blockers have got wider attention, in addition to S-protein and M<sup>pro</sup> modulators as potential therapeutics for COVID-19. So far, no specific drugs have shown promising therapeutic potential against COVID-19. The current study was undertaken to evaluate the therapeutic potential of traditional medicinal plants against COVID-19. The bioactives from the medicinal plants, along with standard drugs, were screened for their binding against S-protein, M<sup>pro</sup> and ACE2 targets using molecular docking followed by molecular dynamics. Based on the higher binding affinity compared with standard drugs, bioactives were selected and further analyzed for their pharmacological properties such as drug-likeness, ADME/<italic>T</italic>-test, biological activities using <italic>in silico</italic> tools. The binding energies of several bioactives analyzed with target proteins were relatively comparable and even better than the standard drugs. Based on Lipinski factors and lower binding energies, seven bioactives were further analyzed for their pharmacological and biological characteristics. The selected bioactives were found to have lower toxicity with a higher GI absorption rate and potent anti-inflammatory and anti-viral activities against targets of COVID-19. Therefore, the bioactives from these medicinal plants can be further developed as phytopharmaceuticals for the effective treatment of COVID-19.</p></abstract><abstract abstract-type="graphical"><title>Graphical Abstract</title><fig id="UF0001" orientation="portrait" position="anchor"><graphic content-type="color" xlink:href="TBSD_A_1842246_UF0001_C"/></fig><p>Traditional medicinal plant bioactives can potentially inhibit SARS-CoV-2 protein targets. Computational investigation revealed that selected medicinal plant bioactives have the optimal pharmacological and biological activities against COVID-19.</p><p>Communicated by Ramaswamy H. Sarma</p></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>COVID-19</kwd><kwd>SARS-CoV-2</kwd><kwd>molecular docking</kwd><kwd>molecular dynamics</kwd><kwd>medicinal plants</kwd></kwd-group><counts><fig-count count="5"/><table-count count="7"/><page-count count="18"/><word-count count="11460"/></counts></article-meta></front><body><sec id="S0001" disp-level="1"><label>1.</label><title>Introduction</title><p>Coronavirus disease (COVID-19) is an infectious disease caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) from the Coronaviridae family and declared as a global pandemic by World Health Organization on 11 March 2020. The new strain of SARS-CoV-2 has lesser virulence but more contagious than its predecessors SARS-CoV and MERS-CoV (Vellingiri et al., <xref rid="CIT0054" ref-type="bibr">2020</xref>). The highly infectious nature of the COVID-19 is due to the molecular evolution that occurred in the genome of SARS-CoV-2 (Andersen et al., <xref rid="CIT0001" ref-type="bibr">2020</xref>). SARS-CoV-2 is a <italic>Betacoronavirus</italic> belonging to the family of enveloped positive single-stranded RNA. SARS-CoV-2 comprises four major structural proteins; among them, spike glycoprotein (S-protein) is an essential protein, involved in the receptor-host selectivity and infection to the host. The S-protein contains the S1 and S2 subunits, S1 subunit functions as the receptor-binding domain, and involved in binding with the host receptor. Whereas the S2 subunit is engaged in the fusion of viral membrane with the host cellular membrane (Lan et al., <xref rid="CIT0027" ref-type="bibr">2020</xref>; Shang et al., <xref rid="CIT0049" ref-type="bibr">2020</xref>). S-protein selectively recognizes human angiotensin-converting enzyme 2 (ACE2) receptor and transmits the virus into the host cell. Intriguingly, the S-protein of SARS-CoV-2 has shown a higher affinity towards the ACE2 receptor compared with SARS-CoV (Lan et al., <xref rid="CIT0027" ref-type="bibr">2020</xref>; Shang et al., <xref rid="CIT0049" ref-type="bibr">2020</xref>). The stronger association of S-protein with ACE2 might be one of the reasons behind the higher infectious efficiency of SARS-CoV-2. Apart from structural proteins, the Main protease (M<sup>pro</sup>) is a non-structural protein and acts as a critical component of the SARS-CoV-2 viral life cycle. M<sup>pro</sup> is a cysteine protease involved in the proteolytic maturation of various polypeptides into non-structural proteins, which are involved in replication and transcription (Jin et al., <xref rid="CIT0022" ref-type="bibr">2020</xref>). Thus, the functionalities of M<sup>pro</sup>, S-protein and ACE2 receptor grasp attention as potential therapeutic targets against COVID-19.</p><p>The primary symptoms of COVID-19 include fever, dry cough, fatigue, headache and diarrhea (Lan et al., <xref rid="CIT0027" ref-type="bibr">2020</xref>). As the SARS-CoV-2 infection progresses, a hyperinflammatory reaction is mediated through exaggerated cytokine response, intense lymphopenia, as well as considerable mononuclear cell infiltration into the various organs (Merad &#x00026; Martin, <xref rid="CIT0033" ref-type="bibr">2020</xref>). The mortality owing to COVID-19 is mainly due to the clinical features in the advanced stages like acute respiratory distress syndrome and severe cardiac injury (Bonow et al., <xref rid="CIT0004" ref-type="bibr">2020</xref>). Currently, there is a lack of specific anti-viral therapeutics and vaccines against COVID-19 (Rodr&#x000ed;guez-Morales et al., <xref rid="CIT0043" ref-type="bibr">2020</xref>). Some clinical studies have aimed to explore the available protease inhibitors, anti-HIV, anti-inflammatory and anti-malarial drugs. However, there is no evidence of the prophylactic and therapeutic effect of these drugs to overcome the morbidity and mortality caused by COVID-19.</p><p>Human civilization has been marred with the occurrence of epidemic and pandemics like SARS-CoV. At the same time, the &#x02018;survival of the fittest&#x02019; taught to develop treatment practices and medicines within the natural bounty. &#x02018;<italic>Ayurveda</italic>&#x02019; is one of the traditional Indian medicinal practices that has appealed attention as complementary approaches against various diseases, including viral infection (Mukhtar et al., <xref rid="CIT0036" ref-type="bibr">2008</xref>). Medicinal plant extracts are known to act as antipyretics, anti-inflammatory, expectorant, analgesic, etc. Several studies have also shown bioactives from medicinal plants function as potential anti-viral agents by boosting the inherent immune system (Ganjhu et al., <xref rid="CIT0016" ref-type="bibr">2015</xref>; Mukhtar et al., <xref rid="CIT0036" ref-type="bibr">2008</xref>). Furthermore, the anti-inflammatory properties of medicinal plants can reduce severe respiratory distress syndrome and acute cardiac injury, which are the leading cause of COVID-19 morbidities (Corn&#x000e9;lio Favarin et al., <xref rid="CIT0008" ref-type="bibr">2013</xref>; Liperoti et al., <xref rid="CIT0030" ref-type="bibr">2017</xref>). It is known that more than 25,000 plant-based formulations have been used in traditional Indian medicine (Vellingiri et al., <xref rid="CIT0054" ref-type="bibr">2020</xref>). Traditional medicines often pioneered the discovery of modern drugs yet underestimated due to the latter&#x02019;s target specificity and translational potential. Unlike modern medicine, a single herb may contain many bioactives that may function alone or in combinations to produce the desired relief. Therefore, in the present study, we investigated the therapeutic prospects of bioactives from the traditional medicinal plants against COVID-19.</p></sec><sec id="S0002" disp-level="1"><label>2.</label><title>Materials and methods</title><sec id="S0002-S2001" disp-level="2"><label>2.1.</label><title>Preparation of ligands and receptors</title><p>Approved drugs for the treatment of HIV (Darunavir, Favipiravir, Nelfinavir, Remdesivir), ACE2 inhibitors (Enalapril, Losartan, Olmesartan) and Dexamethasone were chosen as the standard drugs for docking against SARS-CoV-2 M<sup>pro</sup>, S-protein and ACE2 receptor proteins (Supporting Information <xref rid="t0001" ref-type="table">Table S1</xref>). The standard drugs were selected based on the existing anti-viral activities and ongoing clinical trials against SARS-CoV-2. Based on the literature evidences, 60 bioactives from 22 medicinal plants were selected for docking studies with SARS-CoV-2 M<sup>pro</sup>, S-protein and ACE2 receptor proteins (Supporting Information <xref rid="t0002" ref-type="table">Table S2</xref>). The structural information of ligands, including eight standard drugs and sixty bioactives from the medicinal plants, were retrieved from PubChem (<ext-link ext-link-type="uri" xlink:href="https://pubchem.ncbi.nlm.nih.gov/">https://pubchem.ncbi.nlm.nih.gov/</ext-link>) database (Kim et al., <xref rid="CIT0026" ref-type="bibr">2019</xref>). The ligands were converted from 2D to 3D using Marvin sketch and Open Babel software tools (O&#x02019;Boyle et al., <xref rid="CIT0039" ref-type="bibr">2011</xref>) (MarvinSketch, (<ext-link ext-link-type="uri" xlink:href="https://www.chemaxon.com">https://www.chemaxon.com</ext-link>)). Further, ligand molecules were processed and converted into PDBQT file format using AutoDock Tools (v.1.5.6) of the MGL software package.</p><table-wrap id="t0001" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Binding energies (BEs; kcal/mol) of selected bioactives from medicinal plants with SARS-CoV-2 M<sup>pro</sup>, S- protein and human ACE2 and their chemical interactions with the binding site.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th align="left">&#x000a0;</th><th colspan="3" align="center">SARS-CoV-2 M<sup>pro</sup><hr/></th><th colspan="3" align="center">SARS-CoV-2&#x02009;S-protein<hr/></th><th colspan="3" align="center">Human ACE2<hr/></th></tr><tr><th align="left">Medicinal plants and its bioactives</th><th align="center">BE</th><th align="center">H-bond</th><th align="center">Non-bonded Interactions</th><th align="center">BE</th><th align="center">H-bond</th><th align="center">Non-bonded interactions</th><th align="center">BE</th><th align="center">H-bond</th><th align="center">Non-bonded interactions</th></tr></thead><tbody valign="top"><tr><td align="left">Amla<break/>(<italic toggle="yes">Emblica officinalis)</italic><break/><bold>Pedunculagin</bold></td><td align="left">&#x02013;8.9</td><td align="left">Thr26, His41, <break/>Ser46,<break/>Cys145,<break/>His163</td><td align="left">Thr25, Met49, Phe140, Leu141, Asn142, Gly143, Met165, Glu166,<break/>Gln189</td><td align="left">&#x02013;7.7</td><td align="left">Gln493,<break/>Ser494,<break/>Gly496, Asn501</td><td align="left">Arg403, Glu406, <break/>Lys417, Tyr453,<break/>Leu455, <break/>Tyr505</td><td align="left">&#x02013;7.2</td><td align="left">Asp30, His34, Asp38, Ala386</td><td align="left">Asn33, <break/>Glu37, Ala387, Arg393</td></tr><tr><td align="left">Amla<break/>(<italic toggle="yes">Emblica officinalis)</italic><break/><bold>Punigluconin</bold></td><td align="left">&#x02013;8.5</td><td align="left">Thr24, Thr25,<break/>Cys44, Phe140, His163, Glu166</td><td align="left">Thr26, His41, Thr45, Ser46, Met49, Asn142, Gly143, Cys145, His164, Met165,<break/>His172, Gln189</td><td align="left">&#x02013;7.9</td><td align="left">Arg403,<break/>Glu406, Gln409,<break/>Lys417, Tyr453, Gln493,<break/>Gln496</td><td align="left">Tyr449, Leu455, Ser494, Tyr495, Tyr505</td><td align="left">&#x02013;6.6</td><td align="left">Glu37, Asp38, Ala386, Ala387, Arg393</td><td align="left">Asn33, His34, Lys353, Gln388, Pro389</td></tr><tr><td align="left">Arni<break/>(<italic toggle="yes">Clerodendrum indicum</italic>)<break/><bold>Taraxerol</bold></td><td align="left">&#x02013;7.2</td><td align="center">&#x02013;</td><td align="left">Thr24, Thr25, Thr26, Met49, Leu141, Asn142, Gly143, His164, Met165, Glu166, Gln189</td><td align="left">&#x02013;7.9</td><td align="center">&#x02013;</td><td align="left">Leu452, Leu455, Glu484, <break/>Tyr489,<break/>Phe490, Leu492, <break/>Gln493</td><td align="left">&#x02013;7.0</td><td align="left">Glu35,<break/>Gln76</td><td align="left">Ser19, Gln24, Thr27, Phe28, Lys31, Leu79, Tyr83</td></tr><tr><td align="left">Dhatura<break/><italic toggle="yes">(Datura innoxia)</italic><break/><bold>Daturaolone</bold></td><td align="left">&#x02013;7.3</td><td align="center">&#x02013;</td><td align="left">Thr25, Thr26, Leu27, His41, Met49, Asn142, Gly143, Cys145, Glu166, Gln189</td><td align="left">&#x02013;7.5</td><td align="center">&#x02013;</td><td align="left">Leu452, Leu455, Phe456, <break/>Tyr489, <break/>Phe490, Leu492, <break/>Gln493, Ser494</td><td align="left">&#x02013;7.0</td><td align="left">His34</td><td align="left">Asp38, Tyr41, Gln42, Leu45, Lys353</td></tr><tr><td align="left">Dhatura<break/><italic toggle="yes">(Datura innoxia)</italic><break/><bold>Withametelin</bold></td><td align="left">&#x02013;7.9</td><td align="center">&#x02013;</td><td align="left">Thr26, His41, Met49, Asn142, Gly143, Met165, Glu166, Gln189</td><td align="left">&#x02013;8.0</td><td align="center">&#x02013;</td><td align="left">Leu452, Phe456, Glu484, Tyr489, Phe490, Leu492, Gln493, Ser494</td><td align="left">&#x02013;7.3</td><td align="center">&#x02013;</td><td align="left">Asn33, His34, Glu37, Asp38, Lys353, Pro389, Arg393</td></tr><tr><td align="left">Gaduchi<break/><italic toggle="yes">(Tinospora cordifolia)</italic><break/><bold>Tinosporide</bold></td><td align="left">&#x02013;8.5</td><td align="left">Asn142, Glu166</td><td align="left">His41, Met49, Tyr54, Leu141, Gly143, Ser144, Cys145, His164, Met165, His172, Asp187, Gln189</td><td align="left">&#x02013;6.4</td><td align="left">Arg403, Arg408</td><td align="left">Asp405, Glu406, <break/>Gln409, <break/>Gly416, <break/>Lys417, <break/>Tyr453</td><td align="left">&#x02013;6.5</td><td align="left">His34</td><td align="left">Asp38, Tyr41, Lys353</td></tr><tr><td align="left">Haritaki<break/><italic toggle="yes">(Terminalia chebula)</italic><break/><bold>Chebulagic acid</bold></td><td align="left">&#x02013;6.5</td><td align="left">Thr24,<break/>Thr26, Ser46, Asn142, Gly143, Gln189</td><td align="left">Thr25, His41, Met49</td><td align="left">&#x02013;7.5</td><td align="left">Arg403, Glu406, Tyr453, Gln493, Gly496</td><td align="left">Lys417, Tyr449, Ser494, Tyr495, Tyr505</td><td align="left">&#x02013;6.6</td><td align="left">Lys353</td><td align="left">His34, Glu35, Glu37, Asp38, Tyr41, Arg393</td></tr><tr><td align="left">Haritaki<break/><italic toggle="yes">(Terminalia chebula)</italic><break/><bold>Chebulinic acid</bold></td><td align="left">&#x02013;8.6</td><td align="left">Thr24, Thr25, <break/>Cys44, Leu141, Asn142, <break/>Ser144, <break/>His163, Glu166, Arg188</td><td align="left">Thr26, Leu27, Thr45, Met49, Phe140, Gly143, Met165, His172, Gln189</td><td align="left">&#x02013;6.5</td><td align="left">Arg403, Tyr453, Phe490, Gln493, Gly496</td><td align="left">Lys417, Tyr449, Leu455, Phe456, Tyr489, Ser494, Tyr505</td><td align="left">&#x02013;6.8</td><td align="left">Glu35, Glu37, Asp38,<break/>Arg393</td><td align="left">His34, Tyr41, Lys353</td></tr><tr><td align="left">Haritaki<break/><italic toggle="yes">(Terminalia chebula)</italic><break/><bold>Gallotannins</bold></td><td align="left">&#x02013;8.3</td><td align="left">Thr24,<break/>Phe140, Gly143, His164, <break/>Arg188</td><td align="left">Thr25, Thr26, His41, Met49, Leu141, Asn142 Cys145, Met165, Glu166, Gln189</td><td align="left">&#x02013;7.4</td><td align="left">Arg403, <break/>Glu406, Tyr453,<break/>Leu492, Gln493,<break/>Gly496</td><td align="left">Lys417, Leu455, Phe456, Tyr489, Phe490, Ser494, Tyr495</td><td align="left">&#x02013;7.1</td><td align="left">His34, Asp38,<break/>Ala387,<break/>Arg393</td><td align="left">Asn33, Glu37, Tyr41, Lys353, Ala386, Gln388, Pro389</td></tr><tr><td align="left">Indian Catmint<break/>(<italic toggle="yes">Anisomeles indica</italic>)<break/><bold>Echinacin</bold></td><td align="left">&#x02013;8.9</td><td align="left">Thr24,<break/>Phe140, His164, Glu166, Arg188, Thr190,<break/>Gln192</td><td align="left">Thr25, Thr26, His41, Met49, Asn142, Cys145, Met165, Gln189</td><td align="left">&#x02013;7.9</td><td align="left">Glu484, Phe490</td><td align="left">Tyr449, Leu452, Leu455, Phe456, Tyr489, Ser494</td><td align="left">&#x02013;7.8</td><td align="left">Glu37, Gln96, Ala386, Ala387, Gln388,<break/>Arg393</td><td align="left">Leu29, Asp30, Asn33, His34, Asp38, Tyr41, Val93, Lys353, Pro389</td></tr><tr><td align="left">Indian ginseng<break/><italic toggle="yes">(Withania somnifera)</italic><break/><bold>Withanolide A</bold></td><td align="left">&#x02013;8.2</td><td align="left">Thr26, His41, Glu166</td><td align="left">Thr25, Met49, Phe140, Leu141, Asn142,<break/>Gly143, His164, Met165, Gln189</td><td align="left">&#x02013;7.7</td><td align="left">Glu484</td><td align="left">Leu452, Phe456,<break/>Tyr489, Phe490, Leu492, Gln493, <break/>Ser494</td><td align="left">&#x02013;7.0</td><td align="left">Phe390, Arg393</td><td align="left">Asn33, His34, Glu37, Asp38, Lys353, Pro389</td></tr><tr><td align="left">Liquorice<break/><italic toggle="yes">(Glycyrrhiza glabra)</italic><break/><bold>Glycyrrhizin</bold></td><td align="left">&#x02013;8.2</td><td align="left">Thr24,<break/>Thr25,<break/>Thr26,<break/>His41, Thr45, Ser46, <break/>Gln189</td><td align="left">Leu27, Met49, Tyr118, Leu141, Asn142,<break/>Gly143, <break/>Cys145</td><td align="left">&#x02013;7.1</td><td align="left">Arg403, Gln409, Lys417, <break/>Tyr449,<break/>Gln493, Gly496, Asn501</td><td align="left">Tyr453, Tyr495, Tyr505</td><td align="left">&#x02013;7.0</td><td align="left">His34, Asp38,<break/>Lys68</td><td align="left">Glu35, Glu37, Leu39, Ala71, Phe72, Glu75, Lys353</td></tr><tr><td align="left">Porcupine flower/Vajradanti (<italic toggle="yes">Barleria prionitis)</italic><break/><bold>Barlerinoside</bold></td><td align="left">&#x02013;7.5</td><td align="left">Thr24,<break/>Thr26, <break/>Leu141, Gly143, <break/>Ser144, Glu166, Gln189</td><td align="left">Thr25, Leu27, Ser46, Met49, Phe140, Asn142, Cys145, His163, Met165, Thr190</td><td align="left">&#x02013;7.4</td><td align="left">Arg403, Glu406, Gln409, Phe490, Gln493, Gly496,<break/>Asn501</td><td align="left">Asp405, Lys417, Try449, Tyr453, Leu455, Phe456, Tyr489, Ser494, Tyr505</td><td align="left">&#x02013;6.5</td><td align="left">Asp30, Lys31, <break/>Glu35,<break/>Asp38,<break/>Ala387</td><td align="left">Asn33, His34, Glu37, Leu39, Tyr41, Lys353, Gln388, Pro389, Arg393</td></tr><tr><td align="left">Sage-leaved alangium (<italic toggle="yes">Alangium salvifolium)</italic><break/><bold>Deoxytubulosine</bold></td><td align="left">&#x02013;8.1</td><td align="left">Cys145</td><td align="left">Thr24, Thr25, Thr26, His41, Met49, Phe140, Leu141, Gly143, Met165, Glu166, Asp187, Gln189</td><td align="left">&#x02013;7.2</td><td align="left">Leu492</td><td align="left">Leu455, Phe456, Glu484, Gly485, Tyr489, Phe490, Gln493, Ser494</td><td align="left">&#x02013;6.9</td><td align="center">&#x02013;</td><td align="left">Asn33, His34, Glu37, Asp38, Lys353, Gln388, Pro389, Arg393</td></tr><tr><td align="left">White teak<break/>(<italic toggle="yes">Gmelina arborea</italic>)<break/><bold>Querceitin 3-O-robinobioside</bold></td><td align="left">&#x02013;8.8</td><td align="left">Thr26, Asn142,<break/>Gly143, His163, Glu166, Thr190</td><td align="left">Thr25, Leu27, Phe140, Cys145, His164, Met165, Arg188, Gln189</td><td align="left">&#x02013;7.9</td><td align="left">Arg403, Glu406, Ser494, Gly496, Tyr505</td><td align="left">Lys417, Tyr453, Leu455, Phe456, Tyr495, Phe497</td><td align="left">&#x02013;6.2</td><td align="left">Phe28,<break/>Lys31, Glu35, Glu75<break/>Gln76</td><td align="left">Thr27, Leu79, Met82, Tyr83</td></tr></tbody></table><table-wrap-foot><fn id="TF1"><p>Bioactives are written in boldface.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t0002" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Predicted inhibition constant (Ki) of the selected medicinal plant bioactives and standard drugs against SARS-CoV-2 M<sup>pro</sup>, S-protein and human ACE2.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th align="left">Bioactives </th><th colspan="3" align="center">Inhibition constant (Ki) in &#x000b5;M </th></tr></thead><tbody valign="top"><tr><td align="left">&#x000a0;</td><td align="center">SARS-CoV-2 M<sup>pro</sup></td><td align="center">SARS-CoV-2&#x02009;S-protein </td><td align="center">Human ACE2 </td></tr><tr><td align="left">Pedunculagin </td><td align="center">0.31</td><td align="center">2.31</td><td align="center">5.36</td></tr><tr><td align="left">Punigluconin </td><td align="center">0.60</td><td align="center">1.65</td><td align="center">14.74</td></tr><tr><td align="left">Taraxerol </td><td align="center">5.36</td><td align="center">1.65</td><td align="center">7.51</td></tr><tr><td align="left">Daturaolone </td><td align="center">4.53</td><td align="center">3.23</td><td align="center">7.51</td></tr><tr><td align="left">Withametelin </td><td align="center">1.65</td><td align="center">1.39</td><td align="center">4.53</td></tr><tr><td align="left">Tinosporide </td><td align="center">0.60</td><td align="center">20.64</td><td align="center">14.74</td></tr><tr><td align="left">Chebulagic acid </td><td align="center">17.44</td><td align="center">3.23</td><td align="center">14.74</td></tr><tr><td align="left">Chebulinic acid </td><td align="center">0.51</td><td align="center">17.44</td><td align="center">10.52</td></tr><tr><td align="left">Gallotannins </td><td align="center">0.84</td><td align="center">3.83</td><td align="center">6.34</td></tr><tr><td align="left">Echinacin </td><td align="center">0.31</td><td align="center">1.65</td><td align="center">1.95</td></tr><tr><td align="left">Withanolide A </td><td align="center">0.99</td><td align="center">2.31</td><td align="center">7.51</td></tr><tr><td align="left">Glycyrrhizin </td><td align="center">0.99</td><td align="center">6.34</td><td align="center">7.51</td></tr><tr><td align="left">Barlerinoside </td><td align="center">3.23</td><td align="center">3.83</td><td align="center">17.44</td></tr><tr><td align="left">Deoxytubulosine </td><td align="center">1.18</td><td align="center">5.36</td><td align="center">8.89</td></tr><tr><td align="left">Quercetin 3-O-robinobioside </td><td align="center">0.36</td><td align="center">1.65</td><td align="center">28.92</td></tr><tr><td align="left">Darunavir*</td><td align="center">3.83</td><td align="center">94.11</td><td align="center">40.51</td></tr><tr><td align="left">Dexamethasone*</td><td align="center">10.52</td><td align="center">20.64</td><td align="center">12.45</td></tr><tr><td align="left">Favipiravir*</td><td align="center">306.26</td><td align="center">218.61</td><td align="center">507.82</td></tr><tr><td align="left">Nelfinavir*</td><td align="center">0.84</td><td align="center">14.74</td><td align="center">20.64</td></tr><tr><td align="left">Remdesivir*</td><td align="center">5.36</td><td align="center">14.74</td><td align="center">20.64</td></tr><tr><td align="left">Enalapril*</td><td align="center">&#x02013;</td><td align="center">&#x02013;</td><td align="center">79.51</td></tr><tr><td align="left">Losartan*</td><td align="center">&#x02013;</td><td align="center">&#x02013;</td><td align="center">28.92</td></tr><tr><td align="left">Olmesartan*</td><td align="center">&#x02013;</td><td align="center">&#x02013;</td><td align="center">34.23</td></tr></tbody></table><table-wrap-foot><fn id="TF2"><label>*</label><p>The standard drugs are marked as.</p></fn></table-wrap-foot></table-wrap><p>Receptor PDB structures of the SARS-CoV-2 M<sup>pro</sup> (PDB ID: 6LU7, Resolution: 2.16&#x02009;&#x000c5;; Jin et al., <xref rid="CIT0022" ref-type="bibr">2020</xref>), SARS-CoV-2&#x02009;S-protein (PDB ID: 6W41, Resolution: 3.08&#x02009;&#x000c5;; Yuan et al., <xref rid="CIT0060" ref-type="bibr">2020</xref>) and Human ACE2 (PDB ID: 1R42, Resolution: 2.20&#x02009;&#x000c5;; Towler et al., <xref rid="CIT0051" ref-type="bibr">2004</xref>) protein molecules were retrieved from protein data bank (PDB: <ext-link ext-link-type="uri" xlink:href="http://www.rcsb.org">www.rcsb.org</ext-link>). Protein molecules were prepared by removing water molecules and cofactors, adding polar H bonds and charges using ADT (Morris et al., <xref rid="CIT0035" ref-type="bibr">2009</xref>).</p></sec><sec id="S0002-S2002" disp-level="2"><label>2.2.</label><title>Molecular docking</title><p>Molecular docking of standard drugs and bioactives from medicinal plants with receptor molecules was performed using AutoDock Vina (Trott &#x00026; Olson, <xref rid="CIT0052" ref-type="bibr">2010</xref>). The catalytic site of SARS-CoV-2 M<sup>pro</sup> (His41 and Cys145), receptor binding motif of S-protein (Leu455, Phe486, Glu493 and Ser494) and hotspot binding residues of ACE2 receptor (Lys31 and Lys353) were chosen as binding sites for docking analysis (Jin et al., <xref rid="CIT0022" ref-type="bibr">2020</xref>; Lan et al., <xref rid="CIT0027" ref-type="bibr">2020</xref>; Shang et al., <xref rid="CIT0049" ref-type="bibr">2020</xref>; Veeramachaneni et al., <xref rid="CIT0053" ref-type="bibr">2020</xref>; Yan et al., <xref rid="CIT0057" ref-type="bibr">2020</xref>). Grid box was generated using ADT with dimensions relative to the ligands (XYZ) with a resolution of 1&#x02009;&#x000c5;. The prepared ligand and receptor files were submitted to AutoDock Vina (Trott &#x00026; Olson, <xref rid="CIT0052" ref-type="bibr">2010</xref>). Each docking calculations were repeated three times using different seeds and retaining the remaining values as default. Final protein-ligand interactive models were chosen based on the binding affinity as well as the molecular contacts. The hydrogen bond (H-bond), hydrophobic contacts were calculated using LigPlot+ (Laskowski &#x00026; Swindells, <xref rid="CIT0028" ref-type="bibr">2011</xref>). The binding energy (BE) for each ligand-receptor docked complexes was obtained, and 2D conformations were generated using LigPlot+. Further, the inhibition constant (Ki) for standard drugs and medicinal plant bioactives with SARS-CoV-2 protein targets was determined using the following equation (Onawole et al., <xref rid="CIT0040" ref-type="bibr">2018</xref>).
<disp-formula id="M0001"><alternatives><graphic xlink:href="TBSD_A_1842246_M0001.jpg" position="float" orientation="portrait"/><mml:math id="d2e1274"><mml:mrow><mml:mtext>Ki</mml:mtext><mml:mi mathvariant="normal">
</mml:mi><mml:mo>=</mml:mo><mml:mi mathvariant="normal">
</mml:mi><mml:mn>1</mml:mn><mml:msup><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mtext>Binding</mml:mtext><mml:mi mathvariant="normal">
</mml:mi><mml:mtext>energy</mml:mtext><mml:mo>/</mml:mo><mml:mn>1.366</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:math></alternatives></disp-formula></p></sec><sec id="S0002-S2003" disp-level="2"><label>2.3.</label><title>Screening of ligands based on drug-likeness properties</title><p>The drug-likeness properties of the standard drugs and selected medicinal plant bioactives were screened using Lipinski&#x02019;s rule of five (RO5; <ext-link ext-link-type="uri" xlink:href="http://www.scfbio-iitd.res.in/software/drugdesign/lipinski.jsp">http://www.scfbio-iitd.res.in/software/drugdesign/lipinski.jsp</ext-link>; Lipinski, <xref rid="CIT0031" ref-type="bibr">2004</xref>). Additional drug-likeness features, including lipophilicity, solubility and the drug-likeness score of the ligands were obtained using OSIRIS Property Explorer (<ext-link ext-link-type="uri" xlink:href="https://www.organic-chemistry.org/prog/peo/">https://www.organic-chemistry.org/prog/peo/</ext-link>) and the SWISSADME server (<ext-link ext-link-type="uri" xlink:href="http://www.swissadme.ch/">http://www.swissadme.ch/</ext-link>; Daina et al., <xref rid="CIT0009" ref-type="bibr">2017</xref>).</p></sec><sec id="S0002-S2004" disp-level="2"><label>2.4.</label><title>ADME/Toxicity prediction of the selected ligands</title><p>The ADME/T predictions of bioactive ligands from the medicinal plants and standard drugs were analyzed by the application of the ADMETlab server (<ext-link ext-link-type="uri" xlink:href="http://admet.scbdd.com">http://admet.scbdd.com</ext-link>). The achieved categorical and numerical values were converted into qualitative units based on explanations and interpretations provided by the ADMETlab server (Dong et al., <xref rid="CIT0010" ref-type="bibr">2018</xref>).</p></sec><sec id="S0002-S2005" disp-level="2"><label>2.5.</label><title>Prediction of adverse and toxic effects of ligands</title><p>The toxic properties including LD<sub>50</sub> of the ligands from medicinal plants were analyzed using the ProTox-II server (<ext-link ext-link-type="uri" xlink:href="http://tox.charite.de/protox_II/">http://tox.charite.de/protox_II/</ext-link>) and OSIRIS Property Explorer (<ext-link ext-link-type="uri" xlink:href="https://www.organic-chemistry.org/prog/peo">https://www.organic-chemistry.org/prog/peo</ext-link>). To predict the toxicity class and LD<sub>50</sub>, the Canonical SMILES of ligands were submitted to the ProTox-II server (Drwal et al., <xref rid="CIT0011" ref-type="bibr">2014</xref>). The LD<sub>50</sub> values of standard drugs were retrieved from the DrugBank (<ext-link ext-link-type="uri" xlink:href="http://go.drugbank.com">http://go.drugbank.com</ext-link>) and Cayman chemical websites (<ext-link ext-link-type="uri" xlink:href="https://www.caymanchem.com/">https://www.caymanchem.com/</ext-link>). Other toxicity parameters of both standard drugs and bioactives from medicinal plants were predicted through OSIRIS Property Explorer.</p></sec><sec id="S0002-S2006" disp-level="2"><label>2.6.</label><title>Prediction of biological activity of ligands</title><p>The biological activity scales for the ligands of medicinal plants and standard drugs were predicted by using the Prediction of Activity Spectra for Substances (PASS) program (Filimonov et al., <xref rid="CIT0014" ref-type="bibr">2014</xref>). Briefly, the Canonical SMILES of ligands were used in the PASS-Way2Drug server (<ext-link ext-link-type="uri" xlink:href="http://www.pharmaexpert.ru/passonline/">http://www.pharmaexpert.ru/passonline/</ext-link>) to predict the probability to be active (Pa) and the probability of becoming inactive (Pi). The bioactivity score (BAS) for the selected bioactives from medicinal plants and standard drugs was predicted using Molinspiration web-based tool (<ext-link ext-link-type="uri" xlink:href="http://www.molinspiration.com/cgi-bin/properties">http://www.molinspiration.com/cgi-bin/properties</ext-link>). This web-based tool provides BAS against human receptors and protein molecules like GPCRs, ion channels, nuclear receptors, proteases and kinases.</p></sec><sec id="S0002-S2007" disp-level="2"><label>2.7.</label><title>Molecular dynamics simulations</title><p>The molecular dynamics (MD) simulations were performed on three proteins, M<sup>pro</sup>, S-protein and ACE2 receptor proteins. Nelfinavir was selected as a common inhibitor, as it has shown a higher binding affinity with all the three target proteins. In addition to that based on the binding energies of selected bioactives from medicinal plants, withanolide A was taken for M<sup>pro</sup>, and taraxerol was taken for both S-protein and ACE2 to perform MD. The MD simulations were performed using the AMBER20 package (Case et al., <xref rid="CIT0006" ref-type="bibr">2020</xref>). The ff14SB forcefields were applied for proteins and ions, respectively. The antechamber program was used to develop forcefield for all inhibitors using the gaff2 force field. The topology and coordinated files for protein and complex were created using the <italic>tleap</italic> program. For each complex system including protein and the ligand, TIP3P water molecules were placed in a 12&#x02009;&#x000c5; cubic box in each direction from the surface of the protein. To neutralize the system, 4&#x02009;Na<sup>+</sup>, 2&#x02009;Cl<sup>&#x02013;</sup> and 28&#x02009;Na<sup>+</sup> ions were added to M<sup>pro</sup>, S-protein and ACE2 proteins, respectively. The combined system was submitted to <italic>sander</italic> for energy minimization in four stages, using 5000 cycles steepest descent algorithm. For heating, the NVT ensemble was employed, and the temperature was gradually increased until it reached 300&#x02009;K. Langevin dynamics (thermostat) with a collision frequency of 2.0&#x02009;ps<sup>&#x02212;1</sup> were employed. For the equilibration phase, the NPT ensemble was employed. The SHAKE algorithm was employed to restrict the protein backbone atoms, while inhibitor and solvent molecules allowed free movement. Further, the well-equilibrated complex molecules M<sup>pro</sup> with nelfinavir, M<sup>pro</sup> with withanolide A, S-protein with nelfinavir, S-protein with taraxerol, ACE2 with nelfinavir and ACE2 with taraxerol were subjected to the production phase without any restraints for 100&#x02009;ns MD with a time step of 2 fs. Coordinates and energy parameters were saved every 2&#x02009;ps during the simulation for downstream analysis. The root means square deviation (RMSD) and hydrogen bond analysis were calculated using the <italic>CPPTraj</italic> module on the trajectories obtained.</p></sec><sec id="S0002-S2008" disp-level="2"><label>2.8.</label><title>Binding free energy calculations</title><p>The binding free energy of the protein-inhibitor complexation (&#x00394;<italic>G</italic>) was calculated using molecular mechanics generalized Born surface area (MM-GBSA) and molecular mechanics Poisson-Boltzmann surface area (MM-PBSA). These classical methods were used to evaluate the energy difference between the two ends states of the system such as bound and unbound. These methods are also allowed to perform a more accurate analysis of residue wise contribution to the overall binding of the ligand to a receptor. The BE comprises of bonds, angles, dihedral, electrostatic interactions, Van der Waals interactions, polar and nonpolar solvation energies. Of the 100&#x02009;ns simulation trajectories, the first 10&#x02009;ns were excluded for MM-GBSA/MM-PBSA analysis to facilitate compete equilibration of the system set up. A total of 900 snapshots from the MD simulations were used to calculate the free energies using MM-GBSA, and MM-PBSA methods.</p></sec></sec><sec id="S0003" disp-level="1"><label>3.</label><title>Results and discussion</title><sec id="S0003-S2001" disp-level="2"><label>3.1.</label><title>Molecular docking</title><p>Molecular docking is a computational approach to predict the binding efficiency, and types of interactions between the ligand and receptors (Kamath et al., <xref rid="CIT0024" ref-type="bibr">2015</xref>, <xref rid="CIT0023" ref-type="bibr">2016</xref>; Salam et al., <xref rid="CIT0046" ref-type="bibr">2018</xref>). The bioactives from several medicinal plants, which are traditionally known to have various health benefits, were investigated in the present study and compared their BE with the standard drugs. Among the standard drugs, nelfinavir, an anti-retroviral and protease inhibitor, has shown a stronger affinity towards all three targets of SARS-CoV-2 with the BE of &#x02212;8.3&#x02009;kcal/mol for M<sup>pro</sup>, &#x02212;6.6&#x02009;kcal/mol for S-protein and &#x02212;6.4&#x02009;kcal/mol for ACE2 (Supporting Information <xref rid="t0001" ref-type="table">Table S1</xref>). Many medicinal plant bioactives have also shown a higher binding affinity towards SARS-CoV-2 targets compared to standard drugs. For example, emblicanin A had BE of &#x02212;9.3&#x02009;kcal/mol with M<sup>pro</sup>; rutin had BE of &#x02212;8.2&#x02009;kcal/mol with S-protein and echinacin had BE of &#x02212;7.8&#x02009;kcal/mol with ACE2 (Supporting Information <xref rid="t0002" ref-type="table">Table S2</xref>). Based on the overall BEs of the standard drugs and medicinal plant bioactives, we have set &#x02212;8.5&#x02009;kcal/mol, &#x02212;7.0&#x02009;kcal/mol and &#x02212;6.5&#x02009;kcal/mol as the threshold BEs for M<sup>pro</sup>, S-protein and ACE2 receptors, respectively. The threshold BEs were used to select the medicinal plant bioactives having a higher binding affinity towards target proteins. We have chosen the bioactive that had shown higher binding affinity against at least two or more potential targets with the minimum fixed threshold BE for further analysis. Based on these criteria, 15 medicinal plant bioactives, out of sixty screened, were having equal or more binding affinity with more than two targets of SARS-CoV-2, as highlighted in Supporting Information <xref rid="t0002" ref-type="table">Table S2</xref>.</p><p>Docking results of the selected medicinal plant bioactives with M<sup>pro</sup> illustrate that these bioactives have interactions at the catalytic site of proteases, i.e. His41 and Cys145 similar to the standard drugs (Supporting Information <xref ref-type="fig" rid="F0001 F0002">Fig. S1-S2</xref>). There are 20 amino acids of M<sup>pro</sup> that frequently make H-bonds with the medicinal plant bioactives, and their frequencies of interactions are shown in Supporting Information <xref ref-type="fig" rid="F0003">Fig. S3A</xref>. Similarly, 25 amino acids of M<sup>pro</sup> often make hydrophobic interactions, and their frequencies are shown in Supporting Information <xref ref-type="fig" rid="F0003">Fig. S3B</xref>. Similar to standard drugs, bioactives also had a higher binding affinity, and their interactions at the catalytic dyad suggest that the chosen bioactives may also inhibit the activity of M<sup>pro</sup> and thereby interfere in the process of viral replication as well as transcription. Among the various selected bioactives, pedunculagin (&#x02013;8.9&#x02009;kcal/mol) and echinacin (&#x02013;8.9&#x02009;kcal/mol) has shown the highest BE with M<sup>pro</sup>. Pedunculagin forms H-bond with Thr26, His41, Ser46, Cys145, His163 as well as it had various non-bonded interactions near the binding pocket of M<sup>pro</sup>. Similarly, echinacin forms H-bonds with Thr24, Phe140, His164, Glu166, Arg188, Thr190 and Gln192 in addition, to several non-bonded interactions at the binding pocket of M<sup>pro</sup> (<xref rid="t0001" ref-type="table">Table 1</xref>). The interactions of the bioactives at the binding pockets may likely to inhibit the activity of M<sup>pro</sup>. In addition, <xref ref-type="fig" rid="F0001">Figure 1(A)</xref> shows the common amino acids of M<sup>pro</sup> interacting with the standard drug nelfinavir, and bioactive withanolide A as well as taraxerol.</p><fig id="F0001" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>The 2D interaction plots displaying the interacting and common amino acids of the target proteins with the standard drug nelfinavir (i), and medicinal plant bioactives withanolide A (ii), taraxerol (iii). (A) M<sup>pro</sup> catalytic dyad, (B) S-protein receptor-binding motif, (C) ACE2 receptor. The amino acids of target proteins within 4&#x02009;&#x000c5; proximity are shown, and the hydrogen bonds are represented in dotted lines and colored in green. Hydrophobic contacts are illustrated by an arc with spokes radiating towards the ligand atoms. Common amino acids are shown within red circles.</p></caption><graphic content-type="color" xlink:href="TBSD_A_1842246_F0001_C"/></fig><fig id="F0002" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>MD simulation and MM-PBSA analysis: (A) Root mean square deviation in the positions of protein backbone atoms (in angstrom units) during the MD simulation as superposed with their respective starting structures, calculated over 100&#x02009;ns trajectory. Series color codes are given in the embedded box. Binding energy (kcal/mol) calculated by MM-PBSA analysis calculated from 10 to 100&#x02009;ns of the MD simulations of (B) M<sup>pro</sup>:nelfinavir (black) and M<sup>pro</sup>:withanolide A (red) complex structures, (C) S-protein:nelfinavir (black) and S-protein: taraxerol (red) complex structure and (D) ACE2-nelfinavir (black) and ACE2-taraxerol (red) complex structures.</p></caption><graphic content-type="color" xlink:href="TBSD_A_1842246_F0002_C"/></fig><fig id="F0003" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>Displacements of nelfinavir and taraxerol during MD simulation with S-protein. (A) Cartoon diagram of S-protein: nelfinavir complex. S-protein is shown in the green cartoon. The three poses of nelfinavir are shown in the stick model with different colors and the major interacting residues of S-protein are marked. (B) Cartoon diagram of S-protein:taraxerol complex. The S-protein and taraxerol are colored and shown as A.</p></caption><graphic content-type="color" xlink:href="TBSD_A_1842246_F0003_C"/></fig><p>Recently, Jin et al. (<xref rid="CIT0022" ref-type="bibr">2020</xref>) solved the structure of M<sup>pro</sup> from SARS-CoV-2 (PDB ID: 6LU7), and it is complex with an inhibitor known as N3 (PDB ID: 7BQY; Jin et al., <xref rid="CIT0022" ref-type="bibr">2020</xref>). The N3 inhibitor forms H-bond with amino acids Phe140, Gly143, Cys145, His163, His164, Glu166, Gln189 and Thr190 of M<sup>pro</sup> and hydrophobic contacts with Thr26, Leu27, His41, Leu141, Asn142, Met165, Pro168, His172, Arg188 and Gln192 (Jin et al., <xref rid="CIT0022" ref-type="bibr">2020</xref>). Our docking results also mimic the effects of N3, and these interactions identify some more amino acids of M<sup>pro</sup>, which may facilitate the drug interactions (Supporting Information <xref ref-type="fig" rid="F0001 F0002">Fig. S1 and S2</xref>).</p><p>During viral transmission, the residues of the receptor-binding motif of S-protein bind with ACE2 receptor hotspots. The receptor-binding motif of S-protein consists of Leu455, Phe486, Gln493 and Ser494 residues, which play a critical role in interacting with the ACE2 receptor (Lan et al., <xref rid="CIT0027" ref-type="bibr">2020</xref>; Yan et al., <xref rid="CIT0057" ref-type="bibr">2020</xref>; Yi et al., <xref rid="CIT0059" ref-type="bibr">2020</xref>; Yuan et al., <xref rid="CIT0060" ref-type="bibr">2020</xref>). In our current study, the selected bioactives from medicinal plants as well as standard drugs have shown interaction towards the key residues of the S-protein receptor-binding motif, as shown in Supporting Information Fig. S4 and S5. The frequency of H-bonds and hydrophobic interactions are also summarized in Supporting Information Fig. S6. Among the bioactive from medicinal plants, withametelin from <italic>Dhatura</italic> has the highest binding affinity of &#x02212;8.0&#x02009;kcal/mol, and it has hydrophobic and non-bonded interactions with Leu452, Phe456, Glu484, Tyr489, Phe490, Leu492, Gln493 and Ser494 of S-protein receptor-binding motif, as shown in <xref rid="t0001" ref-type="table">Table 1</xref>. These interactions at the receptor-binding motif suggest the possibility of bioactives attenuating the spike protein-ACE2 interaction. The common amino acids of the S-protein receptor-binding motif interacting with the standard drug nelfinavir, and bioactives withanolide A, as well as taraxerol, are compared and the results are highlighted in <xref ref-type="fig" rid="F0001">Figure 1(B)</xref>.</p><fig id="F0004" orientation="portrait" position="float"><label>Figure 4.</label><caption><p>Graphical representation of per residue contribution. (A) Interacting residues of M<sup>pro</sup>: nelfinavir and M<sup>pro</sup>: withanolide A are shown as histograms. Amino acids of M<sup>pro</sup> interacting with nelfinavir and withanolide A are shown on the <italic>x</italic>-axis and binding energies (kcal/mol) of corresponding residues are shown on the <italic>y</italic>-axis. (B) S-protein: nelfinavir and S-protein:taraxerol and (C) ACE2-nelfinavir, and ACE2-taraxerol.</p></caption><graphic content-type="color" xlink:href="TBSD_A_1842246_F0004_C"/></fig><p>Based on the recent structural and MD studies, many key amino acid residues of the ACE2 receptor are identified in interacting with its partner proteins (Lan et al., <xref rid="CIT0027" ref-type="bibr">2020</xref>; Veeramachaneni et al., <xref rid="CIT0053" ref-type="bibr">2020</xref>). The human ACE2 receptor contains two hotspot residues Lys31 and Lys353. The S-protein recognizes these hotspots, and their interaction is essential for viral infection. The selected bioactives from the medicinal plants have also shown a higher affinity towards hotspot residues of the ACE2 receptor (<xref rid="t0001" ref-type="table">Table 1</xref> and Supporting Information Fig. S8). The interactions of the standard drugs and medicinal plant bioactives were also similar towards hotspot residues of the ACE2 receptor as shown in Supporting Information Fig. S7 and S8. Several chosen bioactives had shown a strong interaction with hotspot Lys353 residues, e.g. echinacin (&#x02013;7.8&#x02009;kcal/mol) and withametelin (&#x02013;7.3&#x02009;kcal/mol). Apart from hotspot Lys353, taraxerol (&#x02013;7.2&#x02009;kcal/mol) and quercetin 3-O-robinobioside (&#x02013;6.2&#x02009;kcal/mol) have shown strong interactions with the hotspot Lys31. These interactions at the hotspot residues suggest that chosen bioactives can act as ACE2 receptor blockers and can hinder the binding of S-protein.</p><p>Overall, the selected medicinal plant bioactives make H-bonds with more than fifteen amino acids of the ACE2 receptor, as shown in Supporting Information Fig. S9A, which are known to interact with its partner proteins frequently. Among them, His34, Glu35, Glu37, Asp38, Ala386, Ala387 and Arg393 show strong and stable interactions with medicinal plant bioactives (Supporting Information Fig. S9A). Besides H-bonding, 29 amino acids of the ACE2 receptor involve in hydrophobic interactions. Among them, Asn33, His34, Glu37, Asp38, Tyr41, Lys353, Gln388, Pro389 and Arg393 residues interact with more than three bioactives (Supporting Information Fig. S9B). The common amino acids of ACE2 receptor interacting with the standard drug nelfinavir, and bioactivities withanolide A, as well as taraxerol, are shown in <xref ref-type="fig" rid="F0001">Figure 1(C)</xref>. Thus, our docking results revealed the interaction of potential bioactives with key amino acid residues of the SARS-CoV-2 M<sup>pro</sup>, S-protein and ACE2 receptor proteins. The bioactives from the selected medicinal plants have shown a stronger affinity with SARS-CoV-2 target proteins. Many of these medicinal plants are well known for their existing anti-viral properties, as outlined in Supporting Information <xref rid="t0003" ref-type="table">Table S3</xref>. Among <italic>Terminalia chebula</italic> possess anti-viral activity against herpes simplex virus-2 and has the efficiency to prevent virus attachment and diffusion into the host cells (Kesharwani et al., <xref rid="CIT0025" ref-type="bibr">2017</xref>).</p><table-wrap id="t0003" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Lipinski&#x02019;s Rule of Five (RO5) for standard drugs.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th align="left">Drugs</th><th align="center">Molecular weight (&#x0003c;500&#x02009;g/mol)</th><th align="center">H-bond donor (&#x0003c;5)</th><th align="center">H-bond acceptor (&#x0003c;10)</th><th align="center">Log P (&#x0003c;5)</th><th align="center">Molar refractivity: (40&#x02013;130)</th><th align="center">Violations</th></tr></thead><tbody valign="top"><tr><td align="left">Darunavir</td><td align="center">547 </td><td align="center">3 </td><td align="center">7 </td><td align="center">4.35 </td><td align="center">144.45 </td><td align="center">2 </td></tr><tr><td align="left">Dexamethasone</td><td align="center">392 </td><td align="center">2 </td><td align="center">5 </td><td align="center">4.27 </td><td align="center">107.78 </td><td align="center">0 </td></tr><tr><td align="left">Enalapril</td><td align="center">376 </td><td align="center">2 </td><td align="center">5 </td><td align="center">3.15 </td><td align="center">100.70 </td><td align="center">0 </td></tr><tr><td align="left">Favipiravir</td><td align="center">157 </td><td align="center">3 </td><td align="center">2 </td><td align="center">&#x02013;0.40 </td><td align="center">27.04 </td><td align="center">0 </td></tr><tr><td align="left">Losartan</td><td align="center">422 </td><td align="center">2 </td><td align="center">1 </td><td align="center">1.63 </td><td align="center">107.52 </td><td align="center">0 </td></tr><tr><td align="left">Nelfinavir</td><td align="center">567 </td><td align="center">3 </td><td align="center">4 </td><td align="center">5.77 </td><td align="center">167.20 </td><td align="center">3 </td></tr><tr><td align="left">Olmesartan</td><td align="center">446 </td><td align="center">3 </td><td align="center">3 </td><td align="center">1.83 </td><td align="center">116.22 </td><td align="center">0 </td></tr><tr><td align="left">Remdesivir</td><td align="center">602 </td><td align="center">6 </td><td align="center">10 </td><td align="center">&#x02013; </td><td align="center">&#x02013; </td><td align="center">3 </td></tr></tbody></table></table-wrap><p>Similarly, bioactives of porcupine (<italic>Barleria prionitis</italic>) and licorice (<italic>Glycyrrhiza glabra</italic>) have shown a higher binding affinity towards S-protein and ACE-2 receptor. Bioactives from medicinal plant <italic>B. prionitis</italic>, is already known to have potent activity against the Respiratory Syncytial Virus (Chen et al., <xref rid="CIT0007" ref-type="bibr">1998</xref>). <italic>G. glabra</italic> has been known to inhibit the viral replication of SARS-CoV and function as an inhibitor of Human Immunodeficiency Virus 1 (HIV-1; Fiore et al., <xref rid="CIT0015" ref-type="bibr">2008</xref>). Estari et al. have shown an extract of <italic>Phyllanthus emblica</italic> (Amla) exert anti-HIV activity via inhibition of HIV reverse transcriptase activity (Estari et al., <xref rid="CIT0013" ref-type="bibr">2012</xref>). In concurrence, we also found that bioactives of amla had a higher binding affinity with the targets of SARS-CoV-2. Overall, our results suggest that the selected medicinal plant bioactives may potentially attenuate the interaction between S-protein and ACE2 receptor as well as inhibit the activity of M<sup>pro</sup>. Thus, inhibition of M<sup>pro</sup> and attenuation of S-protein-ACE2 interaction may affect replication, maturation and transmission of SARS-CoV-2. Furthermore, by analyzing the additional properties such as druggability and pharmacological features one can gain knowledge about the druggable option of these bioactives.</p><p>Further, we determined inhibition constant (Ki) for the bioactives from the medicinal plants and standard drugs. Ki measures the concentration required to produce half-maximum inhibition and 1&#x02013;40&#x02009;&#x000b5;M is considered as a preferred range for a hit compound (Naidoo et al., <xref rid="CIT0038" ref-type="bibr">2020</xref>). The Ki calculated for the bioactives from medicinal plants for all three target proteins are summarized in <xref rid="t0002" ref-type="table">Table 2</xref>. In comparison with bioactives, some of the standard drugs such as favipiravir have demonstrated higher Ki values for all three protein targets. Overall, these results suggest that selected medicinal bioactives have a significant binding affinity towards all the protein targets.</p></sec><sec id="S0003-S2002" disp-level="2"><label>3.2.</label><title>Drug-likeness properties</title><p>The drug-likeness property is an essential parameter to find the ability of a compound to become a drug. Based on the Lipinski&#x02019;s rule of five (RO5), we have analyzed the drug-likeness properties of eight standard drugs (<xref rid="t0003" ref-type="table">Table 3</xref>) and fifteen selected medicinal plant bioactives (<xref rid="t0004" ref-type="table">Table 4</xref>). Among them, bioactives from medicinal plants having a maximum of three violations were selected for analyzing other pharmacological features since the selected standard drug Nelfinavir has shown three violations. Seven bioactives (daturaolone, deoxytubulosine, gallotannins taraxerol, tinosporide, withametelin, withanolide A) have qualified the features of drug-likeness with maximum acceptable violations of three, as highlighted in <xref rid="t0004" ref-type="table">Table 4</xref>.</p><table-wrap id="t0004" orientation="portrait" position="float"><label>Table 4.</label><caption><p>Lipinski&#x02019;s Rule of Five (RO5) for selected bioactives from the medicinal plants.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th align="left">Bioactive </th><th align="center">Molecular weight (&#x0003c;500&#x02009;g/mol) </th><th align="center">H-bond donor (&#x0003c;5) </th><th align="center">H-bond acceptor (&#x0003c;10) </th><th align="center">Log P (&#x0003c;5) </th><th align="center">Molar refractivity: (40&#x02013;130) </th><th align="center">Violations </th><th align="center">Meet RO5 criteria </th></tr></thead><tbody valign="top"><tr><td align="left">Barlerinoside </td><td align="center">930 </td><td align="center">13 </td><td align="center">23 </td><td align="center">5.10 </td><td align="center">217.67 </td><td align="center">5 </td><td align="center">No </td></tr><tr><td align="left">Chebulagic acid </td><td align="center">954 </td><td align="center">10 </td><td align="center">27 </td><td align="center">&#x02013;0.59 </td><td align="center">182.03 </td><td align="center">4 </td><td align="center">No </td></tr><tr><td align="left">Chebulinic acid </td><td align="center">956 </td><td align="center">12 </td><td align="center">27 </td><td align="center">0.900 </td><td align="center">185.99 </td><td align="center">4 </td><td align="center">No </td></tr><tr><td align="left"><bold>Daturaolone</bold></td><td align="center">440 </td><td align="center">1 </td><td align="center">2 </td><td align="center">7.48 </td><td align="center">151.90 </td><td align="center">2 </td><td align="center"><bold>Yes</bold></td></tr><tr><td align="left"><bold>Deoxytubulosine</bold></td><td align="center">459 </td><td align="center">1 </td><td align="center">2 </td><td align="center">5.22 </td><td align="center">139.01 </td><td align="center">2 </td><td align="center"><bold>Yes</bold></td></tr><tr><td align="left">Echinacin </td><td align="center">578 </td><td align="center">6 </td><td align="center">12 </td><td align="center">2.50 </td><td align="center">132.60 </td><td align="center">4 </td><td align="center">No </td></tr><tr><td align="left"><bold>Gallotannins</bold></td><td align="center">636 </td><td align="center">11 </td><td align="center">18 </td><td align="center">0.94 </td><td align="center">127.78 </td><td align="center">3 </td><td align="center"><bold>Yes</bold></td></tr><tr><td align="left">Glycyrrhizin </td><td align="center">822 </td><td align="center">6 </td><td align="center">16 </td><td align="center">7.50 </td><td align="center">216.73 </td><td align="center">5 </td><td align="center">No </td></tr><tr><td align="left">Pedunculagin </td><td align="center">784 </td><td align="center">11 </td><td align="center">22 </td><td align="center">&#x02013;1.78 </td><td align="center">147.68 </td><td align="center">4 </td><td align="center">No </td></tr><tr><td align="left">Punigluconin </td><td align="center">802 </td><td align="center">13 </td><td align="center">23 </td><td align="center">0.78 </td><td align="center">156.52 </td><td align="center">4 </td><td align="center">No </td></tr><tr><td align="left">Quercetin 3-O-robinobioside </td><td align="center">610 </td><td align="center">10 </td><td align="center">16 </td><td align="center">1.83 </td><td align="center">132.33 </td><td align="center">4 </td><td align="center">No </td></tr><tr><td align="left"><bold>Taraxerol</bold></td><td align="center">426 </td><td align="center">1 </td><td align="center">1 </td><td align="center">7.82 </td><td align="center">153.43 </td><td align="center">2 </td><td align="center"><bold>Yes</bold></td></tr><tr><td align="left"><bold>Tinosporide</bold></td><td align="center">374 </td><td align="center">0 </td><td align="center">7 </td><td align="center">2.39 </td><td align="center">91.27 </td><td align="center">0 </td><td align="center"><bold>Yes</bold></td></tr><tr><td align="left"><bold>Withametelin</bold></td><td align="center">436 </td><td align="center">0 </td><td align="center">4 </td><td align="center">5.23 </td><td align="center">129.10 </td><td align="center">1 </td><td align="center"><bold>Yes</bold></td></tr><tr><td align="left"><bold>Withanolide A</bold></td><td align="center">470 </td><td align="center">0 </td><td align="center">6 </td><td align="center">5.88 </td><td align="center">136.95 </td><td align="center">2 </td><td align="center"><bold>Yes</bold></td></tr></tbody></table><table-wrap-foot><fn id="TF3"><p>Bioactives in the bold column were chosen for further analysis based on the minimum acceptable Lipinski&#x02019;s violations.</p></fn></table-wrap-foot></table-wrap><p>The lipophilicity (LogP) is an essential factor in drug-likeness properties, which influences the absorption rate of the drug molecule in the body. A higher LogP value represents a lower absorption. The standard drugs and medicinal plant bioactives were further screened for Ghose filter rule, Veber rule, Egan rule and Muegge rule, which are also associated with the drug-likeness properties. Most of the standard drugs have qualified all the drug-likeness features, as shown in Supporting Information <xref rid="t0001 t0004" ref-type="table">Table S4.1</xref>. In medicinal plant bioactives, tinosporide has qualified all the drug-likeness features, as shown in Supporting Information <xref rid="t0002 t0004" ref-type="table">Table S4.2</xref>. All the other chosen medicinal plant bioactives may have good oral bioavailability and optimal cell permeability as they have low molecular weight and less TPSA value similar to standard drugs. Synthetic accessibility (SA) evaluates the feasibility of the chemical synthesis of the compound. The SA value 1 signifies easy to synthesize, whereas 10 means challenging to synthesize (Ertl &#x00026; Schuffenhauer, <xref rid="CIT0012" ref-type="bibr">2009</xref>). The SA value of these selected bioactives was in between 4.05 and 6.60, which implies that they can be chemically synthesized with a moderate effort.</p></sec><sec id="S0003-S2003" disp-level="2"><label>3.3.</label><title>Prediction of ADME/Toxicity</title><p>ADME/T analysis is aimed to analyze the absorption, distribution, metabolism, excretion and toxicity of the medicinal plant bioactives <italic>in silico</italic>. The ADME/T results are calculated for the standard drugs and bioactives are represented in <xref rid="t0005" ref-type="table">Tables 5</xref> and <xref rid="t0006" ref-type="table">6</xref>, respectively. A desirable compound should have excellent human intestinal absorption (HIA) and Caco-2 cell permeability (Radchenko et al., <xref rid="CIT0042" ref-type="bibr">2016</xref>). Generally, the <italic>in vitro</italic> drug permeability is analyzed using the Caco-2 cell line. We found that most of the chosen medicinal plant bioactives have shown an optimal Caco-2 permeability with higher HIA&#x02013; and GI-absorptions. In contrast, some of the standard drugs including remdesivir and nelfinavir have not shown an optimal Caco-2 permeability and high GI-absorption. Irrespective of absorption and probable toxicity, a recent double-blind study has shown that the administration of remdesivir improved the recovery of patients who were infected with SARS-CoV-2 and lower respiratory tract infections (Beigel et al., <xref rid="CIT0002" ref-type="bibr">2020</xref>). Advantageously, the selected bioactives not only having comparable BEs but also have better pharmacological distributions over selected standard drugs. Further, we also found that bioactives have the potential to inhibit P-glycoprotein (P-gp) as similar to standard drugs. P-gp is one of the important drug efflux transporters involved in maintaining intracellular drug concentrations (S&#x000e8;ve &#x00026; Dumontet, <xref rid="CIT0047" ref-type="bibr">2005</xref>).</p><table-wrap id="t0005" orientation="portrait" position="float"><label>Table 5.</label><caption><p>Results of ADME/<italic>T</italic>-test of the standard drugs.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th colspan="9" align="left"><bold><underline>Absorption</underline></bold></th></tr><tr><th align="left"><bold>Properties</bold></th><th align="center">Darunavir </th><th align="center">Dexamethasone </th><th align="center">Enalapril </th><th align="center">Favipiravir </th><th align="center">Losartan </th><th align="center">Nelfinavir </th><th align="center">Olmesartan </th><th align="center">Remdesivir </th></tr></thead><tbody valign="top"><tr><td rowspan="2">Caco-2 Permeability (Optimal: higher than &#x02212;5.15 Log unit or &#x02212;4.70 or &#x02212;4.80) </td><td align="center">Not optimal </td><td align="center">Optimal </td><td align="center">Not optimal </td><td align="center">Optimal </td><td align="center">Optimal </td><td align="center">Not optimal </td><td align="center">Not optimal </td><td align="center">Not optimal </td></tr><tr><td align="center">&#x02013;5.83&#x02009;cm/s </td><td align="center">&#x02013;4.867&#x02009;cm/s </td><td align="center">&#x02013;5.473&#x02009;cm/s </td><td align="center">&#x02013;4.466&#x02009;cm/s </td><td align="center">&#x02013;5.116&#x02009;cm/s </td><td align="center">&#x02013;5.254&#x02009;cm/s </td><td align="center">&#x02013;5.43&#x02009;cm/s </td><td align="center">&#x02013;6.145&#x02009;cm/s </td></tr><tr><td rowspan="2">Human Intestinal Absorption (HIA) &#x02265;30%: HIA+; &#x0003c;30%: HIA&#x02013; </td><td align="center">&#x02013; </td><td align="center">++</td><td align="center">+</td><td align="center">+</td><td align="center">++</td><td align="center">&#x02013; </td><td align="center">+</td><td align="center">&#x02013; </td></tr><tr><td align="center">(0.426) </td><td align="center">(0.729) </td><td align="center">(0.653) </td><td align="center">(0.542) </td><td align="center">(0.718) </td><td align="center">(0.3) </td><td align="center">(0.583) </td><td align="center">(0.301) </td></tr><tr><td rowspan="2">P-glycoprotein substrate </td><td align="center">&#x02013; </td><td align="center">+</td><td align="center">&#x02013;&#x02013;&#x02013; </td><td align="center">&#x02013;&#x02013;&#x02013; </td><td align="center">++</td><td align="center">+</td><td align="center">+</td><td align="center">&#x02013;&#x02013;&#x02013; </td></tr><tr><td align="center">(0.495) </td><td align="center">(0.5) </td><td align="center">(0.179) </td><td align="center">(0.011) </td><td align="center">(0.716) </td><td align="center">(0.686) </td><td align="center">(0.511) </td><td align="center">(0.142) </td></tr><tr><td rowspan="2">P-glycoprotein inhibitor </td><td align="center">++</td><td align="center">&#x02013; </td><td align="center">+++</td><td align="center">&#x02013;&#x02013;&#x02013; </td><td align="center">++</td><td align="center">++</td><td align="center">+</td><td align="center">++</td></tr><tr><td align="center">(0.858) </td><td align="center">(0.376) </td><td align="center">(0.954) </td><td align="center">(0.042) </td><td align="center">(0.831) </td><td align="center">(0.842) </td><td align="center">(0.665) </td><td align="center">(0.863) </td></tr><tr><td align="left">Bioavailability score</td><td align="center">0.55 </td><td align="center">0.55 </td><td align="center">0.55 </td><td align="center">0.55 </td><td align="center">0.56 </td><td align="center">0.55 </td><td align="center">0.56 </td><td align="center">0.17 </td></tr><tr><td align="left">GI absorption </td><td align="center">Low </td><td align="center">High </td><td align="center">High </td><td align="center">High </td><td align="center">High </td><td align="center">Low </td><td align="center">High </td><td align="center">Low </td></tr><tr><td colspan="9"><underline><bold>Distribution</bold></underline></td></tr><tr><td align="left"><underline><bold>Properties</bold></underline></td><td align="center">Darunavir </td><td align="center">Dexamethasone </td><td align="center">Enalapril </td><td align="center">Favipiravir </td><td align="center">Losartan </td><td align="center">Nelfinavir </td><td align="center">Olmesartan </td><td align="center">Remdesivir </td></tr><tr><td rowspan="2">PPB (Plasma Protein Binding) : 90% </td><td align="center">Optimal </td><td align="center">Less </td><td align="center">Less </td><td align="center">Very Less </td><td align="center">Optimal </td><td align="center">Optimal </td><td align="center">Optimal </td><td align="center">Little less </td></tr><tr><td align="center">(93.448 %) </td><td align="center">(67.738 %) </td><td align="center">(76.383 %) </td><td align="center">(20.55 %) </td><td align="center">(90.596 %) </td><td align="center">(94.791 % </td><td align="center">(91.5 %) </td><td align="center">(89.386 %) </td></tr><tr><td rowspan="2">Blood-Brain Barrier (BBB)BB ratio &#x0003e;&#x02009;=0.1: BBB+; BB ratio &#x0003c;0.1: BBB&#x02013; </td><td align="center">&#x02013;&#x02013;&#x02013;</td><td align="center">+++</td><td align="center">&#x02013;&#x02013;&#x02013;</td><td align="center">+++</td><td align="center">&#x02013;&#x02013;&#x02013;</td><td align="center">&#x02013;&#x02013;&#x02013; </td><td align="center">&#x02013;&#x02013;&#x02013; </td><td align="center">&#x02013;&#x02013;&#x02013;</td></tr><tr><td align="center">(0.187) </td><td align="center">(0.989) </td><td align="center">(0.043) </td><td align="center">(0.996) </td><td align="center">(0.059) </td><td align="center">(0.043) </td><td align="center">(0.034) </td><td align="center">(0.175) </td></tr><tr><td align="left">VD (Volume Distribution) 0.04&#x02009;&#x0223c;&#x02009;20&#x02009;L/kg </td><td align="center">&#x02013;1.228&#x02009;L/kg </td><td align="center">&#x02013;0.036&#x02009;L/kg </td><td align="center">&#x02013;0.278&#x02009;L/kg </td><td align="center">&#x02013;0.686&#x02009;L/kg </td><td align="center">&#x02013;0.111&#x02009;L/kg </td><td align="center">0.234&#x02009;L/kg </td><td align="center">&#x02013;0.823&#x02009;L/kg </td><td align="center">&#x02013;1.167&#x02009;L/kg </td></tr><tr><td colspan="9"><underline><bold>Metabolism</bold></underline></td></tr><tr><td align="left"><underline><bold>Properties</bold></underline></td><td align="center">Darunavir </td><td align="center">Dexamethasone </td><td align="center">Enalapril </td><td align="center">Favipiravir </td><td align="center">Losartan </td><td align="center">Nelfinavir </td><td align="center">Olmesartan </td><td align="center">Remdesivir </td></tr><tr><td rowspan="2">P450 CYP1A2 inhibitor </td><td align="center">&#x02013;&#x02013;&#x02013; </td><td align="center">&#x02013;&#x02013;&#x02013; </td><td align="center">&#x02013;&#x02013;&#x02013; </td><td align="center">&#x02013;&#x02013;&#x02013; </td><td align="center">+</td><td align="center">&#x02013;&#x02013;&#x02013; </td><td align="center">&#x02013;&#x02013;&#x02013; </td><td align="center">&#x02013;&#x02013;&#x02013; </td></tr><tr><td align="center">(0.041) </td><td align="center">(0.023) </td><td align="center">(0.034) </td><td align="center">(0.075) </td><td align="center">(0.6) </td><td align="center">(0.093) </td><td align="center">(0.089) </td><td align="center">(0.138) </td></tr><tr><td rowspan="2">P450 CYP1A2 Substrate </td><td align="center">&#x02013; </td><td align="center">&#x02013; </td><td align="center">&#x02013; </td><td align="center">+</td><td align="center">+</td><td align="center">&#x02013; </td><td align="center">&#x02013; </td><td align="center">&#x02013; </td></tr><tr><td align="center">(0.452) </td><td align="center">(0.413) </td><td align="center">(0.378) </td><td align="center">(0.52) </td><td align="center">(0.516) </td><td align="center">(0.444) </td><td align="center">(0.44) </td><td align="center">(0.304) </td></tr><tr><td rowspan="2">P450 CYP3A4 inhibitor </td><td align="center">++</td><td align="center">&#x02013;&#x02013;&#x02013; </td><td align="center">&#x02013;&#x02013;&#x02013; </td><td align="center">&#x02013;&#x02013;&#x02013; </td><td align="center">+</td><td align="center">+++</td><td align="center">+</td><td align="center">+</td></tr><tr><td align="center">(0.723) </td><td align="center">(0.246) </td><td align="center">(0.069) </td><td align="center">(0.021) </td><td align="center">(0.636) </td><td align="center">(0.907) </td><td align="center">(0.565) </td><td align="center">(0.693) </td></tr><tr><td rowspan="2">P450 CYP3A4 substrate </td><td align="center">+++</td><td align="center">+++</td><td align="center">++</td><td align="center">&#x02013;&#x02013;&#x02013; </td><td align="center">++</td><td align="center">++</td><td align="center">+</td><td align="center">&#x02013; </td></tr><tr><td align="center">(0.916) </td><td align="center">(0.946) </td><td align="center">(0.817) </td><td align="center">(0.264) </td><td align="center">(0.836) </td><td align="center">(0.89) </td><td align="center">(0.592) </td><td align="center">(0.454) </td></tr><tr><td rowspan="2">P450 CYP2C9 inhibitor </td><td align="center">+</td><td align="center">&#x02013;&#x02013;&#x02013; </td><td align="center">&#x02013;&#x02013;&#x02013; </td><td align="center">&#x02013;&#x02013;&#x02013; </td><td align="center">++</td><td align="center">+</td><td align="center">+</td><td align="center">+</td></tr><tr><td align="center">(0.566) </td><td align="center">(0.024) </td><td align="center">(0.048) </td><td align="center">(0.017) </td><td align="center">(0.752) </td><td align="center">(0.571) </td><td align="center">(0.634) </td><td align="center">(0.568) </td></tr><tr><td rowspan="2">P450 CYP2C9 substrate </td><td align="center">++</td><td align="center">&#x02013;&#x02013;&#x02013; </td><td align="center">&#x02013;&#x02013;&#x02013; </td><td align="center">&#x02013;&#x02013;&#x02013; </td><td align="center">++</td><td align="center">++</td><td align="center">+</td><td align="center">&#x02013; </td></tr><tr><td align="center">(0.703) </td><td align="center">(0.022) </td><td align="center">(0.078) </td><td align="center">(0.292) </td><td align="center">(0.791) </td><td align="center">(0.748) </td><td align="center">(0.605) </td><td align="center">(0.332) </td></tr><tr><td rowspan="2">P450 CYP2C19 inhibitor </td><td align="center">&#x02013;&#x02013;&#x02013; </td><td align="center">&#x02013;&#x02013;&#x02013; </td><td align="center">&#x02013;&#x02013;&#x02013; </td><td align="center">&#x02013;&#x02013;&#x02013; </td><td align="center">++</td><td align="center">&#x02013; </td><td align="center">&#x02013; </td><td align="center">&#x02013; </td></tr><tr><td align="center">(0.136) </td><td align="center">(0.089) </td><td align="center">(0.109) </td><td align="center">(0.066) </td><td align="center">(0.842)</td><td align="center">(0.382) </td><td align="center">(0.473) </td><td align="center">(0.472) </td></tr><tr><td rowspan="2">P450 CYP2C19 substrate </td><td align="center">&#x02013; </td><td align="center">&#x02013; </td><td align="center">&#x02013; </td><td align="center">&#x02013;&#x02013;&#x02013; </td><td align="center">&#x02013; </td><td align="center">++</td><td align="center">&#x02013; </td><td align="center">&#x02013;&#x02013;&#x02013; </td></tr><tr><td align="center">(0.408) </td><td align="center">(0.41) </td><td align="center">(0.407) </td><td align="center">(0.216) </td><td align="center">(0.492) </td><td align="center">(0.766) </td><td align="center">(0.346) </td><td align="center">(0.238) </td></tr><tr><td rowspan="2">P450 CYP2D6 inhibitor </td><td align="center">&#x02013; </td><td align="center">+</td><td align="center">&#x02013; </td><td align="center">&#x02013;&#x02013;&#x02013; </td><td align="center">+</td><td align="center">&#x02013; </td><td align="center">&#x02013; </td><td align="center">&#x02013; </td></tr><tr><td align="center">(0.496) </td><td align="center">(0.523) </td><td align="center">(0.337) </td><td align="center">(0.172) </td><td align="center">(0.562) </td><td align="center">(0.456) </td><td align="center">(0.461) </td><td align="center">(0.385) </td></tr><tr><td rowspan="2">P450 CYP2D6 substrate </td><td align="center">+</td><td align="center">&#x02013;&#x02013;&#x02013; </td><td align="center">&#x02013;&#x02013;&#x02013; </td><td align="center">&#x02013;&#x02013;&#x02013; </td><td align="center">&#x02013;&#x02013;&#x02013; </td><td align="center">++</td><td align="center">&#x02013;&#x02013;&#x02013; </td><td align="center">&#x02013; </td></tr><tr><td align="center">(0.636) </td><td align="center">(0.009) </td><td align="center">(0.202) </td><td align="center">(0.218) </td><td align="center">(0.195) </td><td align="center">(0.836) </td><td align="center">(0.223) </td><td align="center">(0.331 </td></tr><tr><td colspan="9"><underline><bold>Excretion</bold></underline></td></tr><tr><td align="left"><underline><bold>Properties</bold></underline></td><td align="center">Darunavir </td><td align="center">Dexamethasone </td><td align="center">Enalapril </td><td align="center">Favipiravir </td><td align="center">Losartan </td><td align="center">Nelfinavir </td><td align="center">Olmesartan </td><td align="center">Remdesivir </td></tr><tr><td rowspan="3">T 1/2 (Half-Life Time; Range: &#x0003e;8&#x02009;h: high; 3&#x02009;h&#x02009;&#x0003c;&#x02009;Cl &#x0003c; 8&#x02009;h: moderate; &#x0003c;3&#x02009;h: low) </td><td align="center">Low </td><td align="center">Low </td><td align="center">Low </td><td align="center">Low </td><td align="center">Low </td><td align="center">Low </td><td align="center">Low </td><td align="center">Low </td></tr><tr><td align="center">(1.32&#x02009;h) </td><td align="center"> (1.27&#x02009;h) </td><td align="center"> (0.95&#x02009;h) </td><td align="center"> (0.69&#x02009;h) </td><td align="center"> (2.01&#x02009;h) </td><td align="center"> (1.58&#x02009;h) </td><td align="center"> (1.74&#x02009;h) </td><td align="center"> (1.42&#x02009;h) </td></tr><tr><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td></tr><tr><td colspan="9">Toxicity</td></tr><tr><td align="left">Properties </td><td align="center">Darunavir </td><td align="center">Dexamethasone </td><td align="center">Enalapril </td><td align="center">Favipiravir </td><td align="center">Losartan </td><td align="center">Nelfinavir </td><td align="center">Olmesartan </td><td align="center">Remdesivir </td></tr><tr><td rowspan="2">hERG (hERG Blockers) </td><td align="center">++</td><td align="center">++</td><td align="center">&#x02013; </td><td align="center">&#x02013;&#x02013;&#x02013; </td><td align="center">++</td><td align="center">++</td><td align="center">++</td><td align="center">+</td></tr><tr><td align="center">(0.7) </td><td align="center">(0.7) </td><td align="center">(0.427) </td><td align="center">(0.171) </td><td align="center">(0.874) </td><td align="center">(0.764) </td><td align="center">(0.743) </td><td align="center">(0.65) </td></tr><tr><td rowspan="2">AMES (Ames Mutagenicity) </td><td align="center">&#x02013;&#x02013;&#x02013; </td><td align="center">&#x02013;&#x02013;&#x02013; </td><td align="center">&#x02013;&#x02013;&#x02013; </td><td align="center">&#x02013;&#x02013;&#x02013; </td><td align="center">+</td><td align="center">&#x02013;&#x02013;&#x02013; </td><td align="center">&#x02013; </td><td align="center">&#x02013;&#x02013;&#x02013; </td></tr><tr><td align="center">(0.13) </td><td align="center">(0.13) </td><td align="center">(0.11) </td><td align="center">(0.232) </td><td align="center">(0.552) </td><td align="center">(0.194) </td><td align="center">(0.362) </td><td align="center">(0.276) </td></tr><tr><td rowspan="2">DILI (Drug-Induced Liver Injury) </td><td align="center">+++</td><td align="center">&#x02013;&#x02013;&#x02013; </td><td align="center">&#x02013; </td><td align="center">++</td><td align="center">++</td><td align="center">+</td><td align="center">++</td><td align="center">++</td></tr><tr><td align="center">(0.936) </td><td align="center">(0.004) </td><td align="center">(0.35) </td><td align="center">(0.786) </td><td align="center">(0.886) </td><td align="center">(0.694) </td><td align="center">(0.774) </td><td align="center">(0.772) </td></tr></tbody></table></table-wrap><table-wrap id="t0006" orientation="portrait" position="float"><label>Table 6.</label><caption><p>Results of ADME/<italic>T</italic>-test of the selected bioactives from medicinal plants.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th colspan="9" align="left">Absorption</th></tr></thead><tbody valign="top"><tr><td colspan="2">Properties<hr/></td><td align="left">Daturaolone<hr/></td><td align="left">Deoxytubulosine<hr/></td><td align="left">Gallotannins<hr/></td><td align="left">Taraxerol<hr/></td><td align="left">Tinosporide<hr/></td><td align="left">Withanolide A<hr/></td><td align="left">Withametelin<hr/></td></tr><tr><td rowspan="2" colspan="2">Caco-2 permeability (Optimal: higher than &#x02212;5.15 Log unit or &#x02212;4.70 or &#x02212;4.80)</td><td align="left">Optimal</td><td align="left">Optimal</td><td align="left">Not optimal</td><td align="left">Optimal</td><td align="left">Optimal</td><td align="left">Optimal</td><td align="left">Optimal</td></tr><tr><td align="left">&#x02013;4.715&#x02009;cm/s</td><td align="left">&#x02013;5.15&#x02009;cm/s</td><td align="left">&#x02013;6.668&#x02009;cm/s</td><td align="left">&#x02013;4.718&#x02009;cm/s</td><td align="left">&#x02013;5.017&#x02009;cm/s</td><td align="left">&#x02013;5.092&#x02009;cm/s</td><td align="left">&#x02013;4.74&#x02009;cm/s</td></tr><tr><td rowspan="2" colspan="2">Human Intestinal Absorption (HIA) &#x02265; 30%: HIA+; &#x0003c;30%: HIA&#x02013;</td><td align="left">+++</td><td align="left">++</td><td align="left">&#x02013;&#x02013;&#x02013;</td><td align="left">+++</td><td align="left">+</td><td align="left">+</td><td align="left">+</td></tr><tr><td align="left">(0.904)</td><td align="left">(0.706)</td><td align="left">(0.177)</td><td align="left">(0.915)</td><td align="left">(0.61)</td><td align="left">(0.611)</td><td align="left">(0.679)</td></tr><tr><td rowspan="2" colspan="2">P-glycoprotein substrate</td><td align="left">&#x02013;&#x02013;&#x02013;</td><td align="left">+++</td><td align="left">&#x02013;&#x02013;&#x02013;</td><td align="left">&#x02013;&#x02013;&#x02013;</td><td align="left">&#x02013;&#x02013;&#x02013;</td><td align="left">&#x02013;&#x02013;&#x02013;</td><td align="left">&#x02013;&#x02013;&#x02013;</td></tr><tr><td align="left">(0.036)</td><td align="left">(0.925)</td><td align="left">(0.005)</td><td align="left">(0.042)</td><td align="left">(0.167)</td><td align="left">(0.087)</td><td align="left">(0.097)</td></tr><tr><td rowspan="2" colspan="2">P-glycoprotein inhibitor</td><td align="left">&#x02013;&#x02013;&#x02013;</td><td align="left">++</td><td align="left">&#x02013;&#x02013;&#x02013;</td><td align="left">&#x02013;&#x02013;&#x02013;</td><td align="left">&#x02013;</td><td align="left">++</td><td align="left">++</td></tr><tr><td align="left">(0.299)</td><td align="left">(0.72)</td><td align="left">(0.123</td><td align="left">(0.263)</td><td align="left">(0.354)</td><td align="left">(0.795)</td><td align="left">(0.765)</td></tr><tr><td colspan="2">Bioavailability score</td><td align="left">0.55</td><td align="left">0.55</td><td align="left">0.17</td><td align="left">0.55</td><td align="left">0.55</td><td align="left">0.55</td><td align="left">0.55</td></tr><tr><td colspan="2">GI absorption</td><td align="left">Low</td><td align="left">High</td><td align="left">Low</td><td align="left">Low</td><td align="left">High</td><td align="left">High</td><td align="left">High</td></tr><tr><td colspan="9">Distribution<hr/></td></tr><tr><td colspan="2">Properties<hr/></td><td align="left">Daturaolone<hr/></td><td align="left">Deoxytubulosine<hr/></td><td align="left">Gallotannins<hr/></td><td align="left">Taraxerol<hr/></td><td align="left">Tinosporide<hr/></td><td align="left">Withanolide A<hr/></td><td align="left">Withametelin<hr/></td></tr><tr><td rowspan="2" colspan="2">PPB (Plasma Protein Binding): 90%</td><td align="left">Less</td><td align="left">Less</td><td align="left">Less</td><td align="left">Less</td><td align="left">Less</td><td align="left">Less</td><td align="left">Less</td></tr><tr><td align="left">(80.905 %)</td><td align="left">(86.055 %)</td><td align="left">(71.82%)</td><td align="left">(80.527 %)</td><td align="left">(64.597 %)</td><td align="left">(88.199 %)</td><td align="left">(84.515 %)</td></tr><tr><td rowspan="2" colspan="2">Blood-Brain Barrier (BBB)BB ratio &#x0003e;&#x02009;=0.1: BBB+; BB ratio &#x0003c;0.1: BBB&#x02013;</td><td align="left">++</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">+++</td><td align="left">+</td><td align="left">++</td><td align="left">++</td></tr><tr><td align="left">(0.867)</td><td align="left">(0.337)</td><td align="left">(0.42)</td><td align="left">(0.951)</td><td align="left">(0.643)</td><td align="left">(0.705)</td><td align="left">(0.892)</td></tr><tr><td colspan="2">VD (Volume Distribution) 0.04&#x02009;&#x0223c;&#x02009;20&#x02009;L/kg</td><td align="left">&#x02013;0.012&#x02009;L/kg</td><td align="left">1.251&#x02009;L/kg</td><td align="left">&#x02013;1.291&#x02009;L/kg</td><td align="left">0.283&#x02009;L/kg</td><td align="left">&#x02013;0.154&#x02009;L/kg</td><td align="left">&#x02013;0.107&#x02009;L/kg</td><td align="left">&#x02013;0.208&#x02009;L/kg</td></tr><tr><td colspan="9">Metabolism<hr/></td></tr><tr><td colspan="2">Properties<hr/></td><td align="left">Daturaolone<hr/></td><td align="left">Deoxytubulosine<hr/></td><td align="left">Gallotannins<hr/></td><td align="left">Taraxerol<hr/></td><td align="left">Tinosporide<hr/></td><td align="left">Withanolide A<hr/></td><td align="left">Withametelin<hr/></td></tr><tr><td rowspan="2" colspan="2">P450 CYP1A2 inhibitor</td><td align="left">&#x02013;&#x02013;&#x02013;</td><td align="left">&#x02013;&#x02013;&#x02013;</td><td align="left">&#x02013;&#x02013;&#x02013;</td><td align="left">&#x02013;&#x02013;&#x02013;</td><td align="left">&#x02013;&#x02013;&#x02013;</td><td align="left">&#x02013;&#x02013;&#x02013;</td><td align="left">&#x02013;&#x02013;&#x02013;</td></tr><tr><td align="left">(0.037)</td><td align="left">(0.08)</td><td align="left">(0.038)</td><td align="left">(0.035)</td><td align="left">(0.062)</td><td align="left">(0.052)</td><td align="left">(0.051)</td></tr><tr><td rowspan="2" colspan="2">P450 CYP1A2 Substrate</td><td align="left">&#x02013;</td><td align="left">+</td><td align="left">&#x02013;&#x02013;&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">+</td></tr><tr><td align="left">(0.352)</td><td align="left">(0.564)</td><td align="left">(0.226)</td><td align="left">(0.372)</td><td align="left">(0.468)</td><td align="left">(0.463)</td><td align="left">(0.566)</td></tr><tr><td rowspan="2" colspan="2">P450 CYP3A4 inhibitor</td><td align="left">&#x02013;&#x02013;&#x02013;</td><td align="left">&#x02013;&#x02013;&#x02013;</td><td align="left">&#x02013;&#x02013;&#x02013;</td><td align="left">&#x02013;&#x02013;&#x02013;</td><td align="left">&#x02013;&#x02013;&#x02013;</td><td align="left">+</td><td align="left">&#x02013;</td></tr><tr><td align="left">(0.076)</td><td align="left">(0.272)</td><td align="left">(0.074)</td><td align="left">(0.046)</td><td align="left">(0.283)</td><td align="left">(0.511)</td><td align="left">(0.35)</td></tr><tr><td rowspan="2" colspan="2">P450 CYP3A4 substrate</td><td align="left">+</td><td align="left">+</td><td align="left">&#x02013;&#x02013;&#x02013;</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">+</td></tr><tr><td align="left">(0.651)</td><td align="left">(0.652)</td><td align="left">(0.202)</td><td align="left">(0.59)</td><td align="left">(0.668)</td><td align="left">(0.693)</td><td align="left">(0.642)</td></tr><tr><td rowspan="2" colspan="2">P450 CYP2C9 inhibitor</td><td align="left">&#x02013;&#x02013;&#x02013;</td><td align="left">&#x02013;&#x02013;&#x02013;</td><td align="left">&#x02013;&#x02013;&#x02013;</td><td align="left">&#x02013;&#x02013;&#x02013;</td><td align="left">&#x02013;&#x02013;&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;&#x02013;&#x02013;</td></tr><tr><td align="left">(0.057)</td><td align="left">(0.099)</td><td align="left">(0.144)</td><td align="left">(0.028)</td><td align="left">(0.179)</td><td align="left">(0.31)</td><td align="left">(0.277)</td></tr><tr><td rowspan="2" colspan="2">P450 CYP2C9 substrate</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;&#x02013;&#x02013;</td><td align="left">&#x02013;&#x02013;&#x02013;</td><td align="left">&#x02013;&#x02013;&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left">(0.361)</td><td align="left">(0.328)</td><td align="left">(0.353)</td><td align="left">(0.274)</td><td align="left">(0.287)</td><td align="left">(0.273)</td><td align="left">(0.3)</td></tr><tr><td rowspan="2" colspan="2">P450 CYP2C19 inhibitor</td><td align="left">&#x02013;&#x02013;&#x02013;</td><td align="left">&#x02013;&#x02013;&#x02013;</td><td align="left">&#x02013;&#x02013;&#x02013;</td><td align="left">&#x02013;&#x02013;&#x02013;</td><td align="left">&#x02013;&#x02013;&#x02013;</td><td align="left">&#x02013;&#x02013;&#x02013;</td><td align="left">&#x02013;&#x02013;&#x02013;</td></tr><tr><td align="left">(0.118)</td><td align="left">(0.17)</td><td align="left">(0.042)</td><td align="left">(0.134)</td><td align="left">(0.103)</td><td align="left">(0.165)</td><td align="left">(0.225)</td></tr><tr><td rowspan="2" colspan="2">P450 CYP2C19 substrate</td><td align="left">&#x02013;</td><td align="left">+</td><td align="left">&#x02013;&#x02013;&#x02013;</td><td align="left">&#x02013;</td><td align="left">+</td><td align="left">&#x02013;</td><td align="left">+</td></tr><tr><td align="left">(0.426)</td><td align="left">(0.56)</td><td align="left">(0.208)</td><td align="left">(0.406)</td><td align="left">(0.61)</td><td align="left">(0.472)</td><td align="left">(0.687)</td></tr><tr><td rowspan="2" colspan="2">P450 CYP2D6 inhibitor</td><td align="left">&#x02013;&#x02013;&#x02013;</td><td align="left">++</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;&#x02013;&#x02013;</td><td align="left">&#x02013;&#x02013;&#x02013;</td></tr><tr><td align="left">(0.226)</td><td align="left">(0.702)</td><td align="left">(0.361)</td><td align="left">(0.318)</td><td align="left">(0.349)</td><td align="left">(0.297)</td><td align="left">(0.28)</td></tr><tr><td rowspan="2" colspan="2">P450 CYP2D6 substrate</td><td align="left">&#x02013;</td><td align="left">++</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;&#x02013;&#x02013;</td><td align="left">&#x02013;&#x02013;&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left">(0.305)</td><td align="left">(0.799)</td><td align="left">(0.355)</td><td align="left">(0.36)</td><td align="left">(0.23)</td><td align="left">(0.298)</td><td align="left">(0.346)</td></tr><tr><td colspan="9">Excretion<hr/></td></tr><tr><td colspan="2">Properties<hr/></td><td align="left">Daturaolone<hr/></td><td align="left">Deoxytubulosine<hr/></td><td align="left">Gallotannins<hr/></td><td align="left">Taraxerol<hr/></td><td align="left">Tinosporide<hr/></td><td align="left">Withanolide A<hr/></td><td align="left">Withametelin<hr/></td></tr><tr><td rowspan="2" colspan="2">T 1/2 (Half Life Time; &#x0003e;8&#x02009;h: high; 3h&#x02009;&#x0003c;&#x02009;Cl &#x0003c; 8&#x02009;h: moderate; &#x0003c;3&#x02009;h: low)</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td><td align="left">Low</td></tr><tr><td align="left">(1.67&#x02009;h)</td><td align="left">(1.79&#x02009;h)</td><td align="left">(1.86&#x02009;h)</td><td align="left">(1.88&#x02009;h)</td><td align="left">(1.19&#x02009;h)</td><td align="left">(1.6&#x02009;h)</td><td align="left">(1.91&#x02009;h)</td></tr><tr><td colspan="9">Toxicity<hr/></td></tr><tr><td colspan="2">Properties<hr/></td><td align="left">Daturaolone<hr/></td><td align="left">Deoxytubulosine<hr/></td><td align="left">Gallotannins<hr/></td><td align="left">Taraxerol<hr/></td><td align="left">Tinosporide<hr/></td><td align="left">Withanolide A<hr/></td><td align="left">Withametelin<hr/></td></tr><tr><td rowspan="2" colspan="2">hERG (hERG Blockers)</td><td align="left">&#x02013;</td><td align="left">++</td><td align="left">+</td><td align="left">&#x02013;</td><td align="left">&#x02013;&#x02013;&#x02013;</td><td align="left">&#x02013;</td><td align="left">+</td></tr><tr><td align="left">(0.455)</td><td align="left">(0.844)</td><td align="left">(0.632)</td><td align="left">(0.468)</td><td align="left">(0.188)</td><td align="left">(0.449)</td><td align="left">(0.519)</td></tr><tr><td rowspan="2" colspan="2">AMES (Ames Mutagenicity)</td><td align="left">&#x02013;&#x02013;&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;&#x02013;&#x02013;</td><td align="left">&#x02013;&#x02013;&#x02013;</td><td align="left">&#x02013;&#x02013;&#x02013;</td><td align="left">&#x02013;&#x02013;&#x02013;</td></tr><tr><td align="left">(0.07)</td><td align="left">(0.33)</td><td align="left">(0.354)</td><td align="left">(0.036)</td><td align="left">(0.266)</td><td align="left">(0.29)</td><td align="left">(0.196)</td></tr><tr><td rowspan="2" colspan="2">DILI (Drug Induced Liver Injury)</td><td align="left">&#x02013;</td><td align="left">&#x02013;&#x02013;&#x02013;</td><td align="left">++</td><td align="left">&#x02013;&#x02013;&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;&#x02013;&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left">(0.468)</td><td align="left">(0.224)</td><td align="left">(0.744)</td><td align="left">(0.214)</td><td align="left">(0.368)</td><td align="left">(0.278)</td><td align="left">(0.446)</td></tr></tbody></table></table-wrap><p>After intestinal absorption, the bioactive molecules circulate into the different parts of the body through blood. Most of the selected bioactives have shown a lesser affinity to bind with plasma protein (PPB) in contrast to some of the standard drugs and, therefore, they are expected to be freely available at the required tissue or organ. After the circulation, the bioactives are metabolized in the liver by the family of the Cytochrome P450 enzymes (Glue &#x00026; Clement, <xref rid="CIT0017" ref-type="bibr">1999</xref>). Here, few drugs and bioactives functioned as the substrate for these enzymes; consequently, the corresponding CYP450 enzyme might metabolize them.</p></sec><sec id="S0003-S2004" disp-level="2"><label>3.4.</label><title>Toxicity prediction of bioactives</title><p>Toxicity prediction is one major factor in scoring any compound as a drug. The <italic>in silico</italic> toxicological profile of the medicinal plant bioactives was determined by the ProTox-II server and compared with the standard drugs (Drwal et al., <xref rid="CIT0011" ref-type="bibr">2014</xref>). The LD<sub>50</sub> values of standard drugs and predictive different organ toxicity are given in Supporting Information <xref rid="t0001 t0005" ref-type="table">Table S5.1</xref>. Globally Harmonized System of Classification and Labelling of Chemicals classified different classes of toxicity of orally consumed compounds, described in Supporting Information <xref rid="t0002 t0005" ref-type="table">Table S5.2</xref>. Bioactives from medicinal plants shown a range of LD<sub>50</sub> values. Daturaolone and taraxerol were non-toxic as their LD<sub>50</sub> was 8800&#x02009;mg/kg, 70,000&#x02009;mg/kg, respectively. In contrast, withanolide A was falling under class 2 toxicity. Structural modification is one of the new techniques to reduce the toxicity of any compounds. Recently, different chemical strategies such as applying the structural alert in molecules can reduce the toxicity. These structural alerts reduce the toxicity by partial replacement or a full replacement, or by reducing the electronic density or by introducing the structural element involved in metabolism (Limban et al., <xref rid="CIT0029" ref-type="bibr">2018</xref>). The level of toxicity also can be reduced by consuming them as dietary formulations rather than purified compounds or drugs. Therefore, toxicity can be reduced by structural alteration or by chemical strategies. Most of the chosen bioactives did not show any hepatotoxicity, mutagenicity and cytotoxicity.</p></sec><sec id="S0003-S2005" disp-level="2"><label>3.5.</label><title>Prediction of biological activities</title><p>PASS is used to estimate the probable biological activities of drug-like compounds (Filimonov et al., <xref rid="CIT0014" ref-type="bibr">2014</xref>). Different biological activities, including anti-viral activities, were assessed by determining the Pa and Pi values. The PASS analysis of standard drugs and bioactives from the medicinal plants is presented in Supporting Information <xref rid="t0001 t0002 t0006" ref-type="table">Table S6.1 and S6.2</xref>, respectively. The Pa value towards 1, indicates the ligand is probably &#x02018;active&#x02019;, whereas the Pi value implies that the ligand is probably &#x02018;inactive&#x02019;. Approximately seventeen proposed biological activities were determined. The results have shown that some of the medicinal plant bioactives can act as potent anti-inflammatory and immunosuppressant. However, most of the standard drugs have shown different anti-viral properties, at the same time, some of them also have shown immunostimulatory properties. The chosen bioactives also exert various biological activities, which can act as complementary medicine during the COVID-19 disease.</p><p>Similarly, the BAS of the selected medicinal plant bioactives were evaluated for various biological ligands and enzymes. It is known that if the BAS of a ligand is &#x0003c; &#x02212;0.50, then it is inactive on that target receptors, likewise, if BAS is &#x02212;0.50 to 0.00, ligands are moderately active, and if BAS is &#x0003e;0.00, then it is biologically active against human receptor and proteins like GPCRs, ion channels, nuclear receptor, proteases and kinases (Mishra et al., <xref rid="CIT0034" ref-type="bibr">2018</xref>). Our results of selected medicinal plant bioactives exhibited biological activities and have a physiological effect. Further, standard drugs were shown to have high activity towards protease inhibition, similarly, the selected medicinal plant bioactives also demonstrated moderate to high activity against protease inhibition, apart from having an activity like enzyme inhibition, and interaction with nuclear and GPCR ligand receptors as shown in Supporting Information <xref rid="t0007" ref-type="table">Table S7</xref>. The protease inhibitory activity of selected medicinal plant bioactives provides further evidence that these bioactives can bind and potentially modulates the main proteases of SARS-CoV-2.</p><table-wrap id="t0007" orientation="portrait" position="float"><label>Table 7.</label><caption><p>MM-GBSA and MM-PBSA calculations of binding energy for six selected complex molecules.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th align="left">Analysis type</th><th align="center">Energy Component</th><th align="center">M<sup>pro</sup>-Nelfinavir</th><th align="center">M<sup>pro</sup>-Withanolide A</th><th align="center">S-protein-Nelfinavir</th><th align="center">S-protein-Taraxerol</th><th align="center">ACE2-Nelfinavir</th><th align="center">ACE2-Taraxerol</th></tr></thead><tbody valign="top"><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td colspan="6">DeltaG (kcal/mol)</td></tr><tr><td rowspan="5">GBSA</td><td align="left">VDWAAL</td><td align="left">&#x02013;55.9 (5.4)</td><td align="left">&#x02013;35.3 (4.7)</td><td align="left">&#x02013;14.8 (8.7)</td><td align="left">&#x02013;22.9 (5.1)</td><td align="left">&#x02013;33.7 (4.7)</td><td align="left">&#x02013;30.1 (4.4)</td></tr><tr><td align="left">EEL</td><td align="left">&#x02013;17.7 (6.4)</td><td align="left">&#x02013;12.0 (6.8)</td><td align="left">&#x02013;9.3 (8.1)</td><td align="left">&#x02013;0.8 (2.0)</td><td align="left">&#x02013;32.5 (7.7)</td><td align="left">&#x02013;1.4 (3.4)</td></tr><tr><td align="left">EGB</td><td align="left">28.8 (5.3)</td><td align="left">23.7 (5.2)</td><td align="left">14.2 (9.2)</td><td align="left">7.9 (2.1)</td><td align="left">44.2 (6.7)</td><td align="left">8.8 (2.8)</td></tr><tr><td align="left">ESURF</td><td align="left">&#x02013;6.8 (0.6)</td><td align="left">&#x02013;4.4 (0.5)</td><td align="left">&#x02013;1.9 (1.1)</td><td align="left">&#x02013;2.5 (0.5)</td><td align="left">&#x02013;4.3 (0.6)</td><td align="left">3.6 (0.5)</td></tr><tr><td align="left">Total</td><td align="left">&#x02013;51.7 (6.3)</td><td align="left">&#x02013;27.9 (5.4)</td><td align="left">&#x02013;11.8 (7.8)</td><td align="left">&#x02013;18.2 (4.5)</td><td align="left">&#x02013;26.3 (4.4)</td><td align="left">&#x02013;26.2 (4.2)</td></tr><tr><td rowspan="5">PBSA</td><td align="left">VDWAAL</td><td align="left">&#x02013;55.9 (5.4)</td><td align="left">&#x02013;35.3 (4.7)</td><td align="left">&#x02013;14.8 (8.7)</td><td align="left">&#x02013;22.9 (5.1)</td><td align="left">&#x02013;33.7 (4.7)</td><td align="left">&#x02013;30.1 (4.4)</td></tr><tr><td align="left">EEL</td><td align="left">&#x02013;17.7 (6.4)</td><td align="left">&#x02013;12.0 (6.8)</td><td align="left">&#x02013;9.3 (8.1)</td><td align="left">&#x02013;0.8 (2.0)</td><td align="left">&#x02013;32.5 (7.7)</td><td align="left">&#x02013;1.4 (3.4)</td></tr><tr><td align="left">EPB</td><td align="left">39.1 (6.0)</td><td align="left">24.9 (6.6)</td><td align="left">13.0 (9.1)</td><td align="left">6.3 (2.4)</td><td align="left">46.3 (8.3)</td><td align="left">7.9 (2.9)</td></tr><tr><td align="left">ENPOLAR</td><td align="left">&#x02013;39.0 (3.0)</td><td align="left">&#x02013;25.0 (3.1)</td><td align="left">&#x02013;11.2 (6.8)</td><td align="left">&#x02013;15.2 (3.0)</td><td align="left">&#x02013;24.8 (3.0)</td><td align="left">&#x02013;21.8 (2.8)</td></tr><tr><td align="left">Total</td><td align="left">&#x02013;3.1 (6.4)</td><td align="left">&#x02013;0.7 (4.4)</td><td align="left">&#x02013;2.4 (4.0)</td><td align="left">&#x02013;4.2 (3.0)</td><td align="left">&#x02013;2.4 (4.9)</td><td align="left">&#x02013;7.3 (3.2)</td></tr></tbody></table></table-wrap></sec><sec id="S0003-S2006" disp-level="2"><label>3.6.</label><title>MD simulation</title><p>Unrestrained MD simulations were performed for M<sup>pro</sup> with nelfinavir, M<sup>pro</sup> with withanolide A, S-protein with nelfinavir, S-protein with taraxerol, ACE2 with nelfinavir and ACE2 with taraxerol complexes, each for 100&#x02009;ns. In the M<sup>pro</sup>-nelfinavir complex, nelfinavir is fairly stable throughout the simulation at the binding pocket (Supporting Information video S1). Similarly, in M<sup>pro</sup>-withanolide A complex (Supporting Information video S2), withanolide A molecule is stable and remains inside the pocket. From the RMSD plot, it is evident that the backbone of the M<sup>pro</sup> did not converge in both cases. The RMSD of the M<sup>pro</sup>-nelfinavir complex is sampling higher values after 70&#x02009;ns, whereas in M<sup>pro</sup>-withanolide A complex, the RMSD is reaching a maximum of around 40&#x02009;ns, then is stable at 4&#x02009;&#x000c5; minimum and gain the stability (<xref ref-type="fig" rid="F0002">Figure 2(A)</xref>). Since the stability of ligand binding at its pocket is evident from the simulation videos, the fluctuations in the RMSD are likely due to changes in the regions other than its catalytic site; hence, these do not alter our main discussion points.</p><p>The S-protein-nelfinavir complex (Supporting Information video S3) showed quite interesting binding patterns during the simulations. The nelfinavir molecule is initially bound at the cavity formed by the amino acids Leu452-Phe456, and Glu484-Gly496 of S-protein, and it retained its pose up to 24&#x02009;ns. It then dissociates from the binding pocket, floats free among the bulk solvent and binds again to the protein between 40 and 69&#x02009;ns. It dissociates from the second position too and it finally moves to a third pose at a site diametrically across the molecule from the starting pocket and stays stable from 80 to 100&#x02009;ns (<xref ref-type="fig" rid="F0003">Figure 3(A)</xref>). The S-protein-taraxerol complex, taraxerol moves away from its initial binding pose taking up a second position after 15&#x02009;ns, reaches its final position around 30&#x02009;ns and remains stable during the rest of the simulation (<xref ref-type="fig" rid="F0003">Figure 3(B)</xref>). The recent X-ray crystallographic structural studies of S-protein with monoclonal antibody CR3022 revealed that the CR3022 binds the same site where the nelfinavir and taraxerol move to the final position (third pose; Huo et al., <xref rid="CIT0021" ref-type="bibr">2020</xref>). The authors postulated that the CR3022 binding to amino acids 369&#x02013;392, and 427&#x02013;430 of S-protein, leads to neutralization mechanism by destroying the prefusion spike conformation. <xref ref-type="fig" rid="F0002">Figure 2(A)</xref> plot shows that S-protein &#x02013; nelfinavir or taraxerol complex structures remain stable with their RMSD mostly staying below 2&#x02009;&#x000c5; from their starting respective structures.</p><p>In the ACE2-nelfinavir complex (Supporting Information video S5), the nelfinavir is stable in the entire study. In the ACE2-taraxerol complex study (Supporting Information video S6), the taraxerol molecule is flipping from the docked position in early stages around 1.7&#x02009;ns, then become stable and change its orientation around 84&#x02009;ns simulation. The RMSD plot of ACE2-nelfinavir and ACE2-taraxerol shows that the overall structure of ACE2-nelfinavir is relatively more stable than the ACE2-taraxerol complex structure during the course of the MD simulation (<xref ref-type="fig" rid="F0002">Figure 2(A)</xref>).</p></sec><sec id="S0003-S2007" disp-level="2"><label>3.7.</label><title>MM-GBSA and MM-PBSA calculations</title><p>Binding free energies calculated using MM-GBSA and MM-PBSA methods are shown in <xref rid="t0007" ref-type="table">Table 7</xref> for all the six complex molecules. Initial 10&#x02009;ns frames or omitted for equilibration, and a total of 900 frames out of the remaining 90&#x02009;ns simulations were used to obtain the free energy all the systems. In terms of MM-GBSA M<sup>pro</sup>-nelfinavir showed the highest energy (&#x02013;51.7&#x02009;kcal/mol). M<sup>pro</sup>-withanolide A (&#x02013;27.9&#x02009;kcal/mol), ACE2-nelfinavir (&#x02013;26.3&#x02009;kcal/mol) and ACE2-taraxerol (&#x02013;26.2&#x02009;kcal/mol) showed similar energies. In terms of MM-PBSA, ACE2-taraxerol (&#x02013;7.3&#x02009;kcal/mol) showed the highest affinity than other complex molecules. The BE versus time graphs (<xref ref-type="fig" rid="F0002">Figure 2(B&#x02013;D)</xref>) is drawn for all the complexes. In terms of M<sup>pro</sup> complexes, both nelfinavir and taraxerol showed similar energies, whereas the ACE2, and S-protein complexes, taraxerol shows better binding energies than the standard drug nelfinavir. It should be noted that taraxerol has only one hydroxyl and seven methyl groups attached to the pentacyclic triterpenoid. The taraxerol possess anti-tumor (Hong et al., <xref rid="CIT0020" ref-type="bibr">2016</xref>), and anti-inflammatory (Yao et al., <xref rid="CIT0058" ref-type="bibr">2013</xref>) activities, and one of the abundantly available medicinal phytochemicals that can be extracted from more than 50 medicinal plants (Sharma &#x00026; Zafar, <xref rid="CIT0050" ref-type="bibr">2015</xref>).</p><p>In addition to that, we analyzed the contribution of each residue to the BE using the decomposition tool present in the AMBER: MM-GBSA method. Forty residues of M<sup>pro</sup> has shown significant interaction with nelfinavir and/or withanolide A (<xref ref-type="fig" rid="F0004">Figure 4(A)</xref>). Among those His41, Met49, Met165 and Gln189 are common residues that showed favorable binding energies with the medicinal phytochemical compounds. Apart from that Thr25, Leu29, Asn142, Gly143, Cys145, His164 and Gln189 of M<sup>pro</sup> showed good interaction with nelfinavir, and Ser46, Leu50, Asp187, Arg188, Gln189, Asn142 and Cys145 of M<sup>pro</sup> showed higher binding energies with withanolide A. Recent studies on M<sup>pro</sup> with bioactive molecules from the tea plant, showed similar interactions (Bhardwaj et al., <xref rid="CIT0003" ref-type="bibr">2020</xref>). Among those residues, His41 and Cys145 form a catalytic dyad located at the interface between domains I and II, and most of the remaining residues are involved in substrate binding and dimerization (Goyal &#x00026; Goyal, <xref rid="CIT0018" ref-type="bibr">2020</xref>). Thr478, Pro479, Cys480, Asn481, Gly482 and Val483 of S-protein show better binding energies with nelfinavir, whereas the taraxerol have significant binding energies at three different positions Ser359-Val363, Cys391-Phe392 and Pro521-Cys525 (<xref ref-type="fig" rid="F0004">Figure 4(B)</xref>). Recent mutagenesis studies identified that Arg439, Lys452, Leu455, Ala475, Glu484, Phe486, Gln493, Gln498, Pro499 and Asn501 of S-protein play a major role in human ACE2 binding (Yi et al., <xref rid="CIT0059" ref-type="bibr">2020</xref>), and these residues are closely matching with our results. It is also interesting to note that the taraxerol is having reasonable binding energies with three cysteine residues (Cys361, Cys391 and Cys525), which play role in stabilizing the secondary structure of S-protein (Lan et al., <xref rid="CIT0027" ref-type="bibr">2020</xref>). The ACE2 complexes, His34 and Phe28 of ACE2 are the two major amino acids that have a higher binding affinity with nelfinavir and taraxerol, respectively (<xref ref-type="fig" rid="F0004">Figure 4(C)</xref>). Interestingly His34 of ACE2 is the common residues interacting with both SARS-Cov S-protein and SARS-Cov-2&#x02009;S-protein (Lan et al., <xref rid="CIT0027" ref-type="bibr">2020</xref>).</p><p>The hydrogen bonds formed during the simulation time in all the six complex molecules were calculated using CPPTRAJ (Roe &#x00026; Cheatham, <xref rid="CIT0044" ref-type="bibr">2013</xref>). The amino acids His164, Gly143 (M<sup>pro</sup>-nelfinavir), His164, Gln189 (M<sup>pro</sup>-withanolide A), Glu484, Cys480 (S-protein-nelfinavir), Gly381, Glu484 (S-protein-taraxerol), His34, Asp30 (ACE2-nelfinavir) and Gln76, Glu75 (ACE2-taraxerol) are the top two residues interacting with the respective ligands.</p></sec></sec><sec id="S0004" disp-level="1"><label>4.</label><title>Conclusion</title><p>The infectious pandemic COVID-19 has emerged as a massive threat to humankind. The main challenges are to control the spread of the disease, developing immunity as the preventive as well as prophylactic, and discovering therapeutics in a feasible time. Nature has always blessed us with plentiful remedies like herbs and medicinal plants for numerous ailments. Therefore, the virtual screening based on molecular docking was executed to identify potential bioactives from medicinal plants as effective inhibitors of M<sup>pro</sup>, S-protein and ACE2. We found many bioactives from the medicinal plants have shown either comparable or better binding affinity with targets of SARS-CoV-2 with desirable pharmacological properties over the standard drugs. Further, we also observed that the selected bioactives have better intestinal and GI absorptions and lower toxicity than the standard drugs used. Therefore, these selected bioactives may further be developed as pharmacological inhibitors against SARS-CoV-2 target proteins involved in viral replication, propagation and transmission. Among them, taraxerol from <italic>Clerodendrum</italic> has shown potential anti-viral activities with desirable pharmacological features (Sharma &#x00026; Zafar, <xref rid="CIT0050" ref-type="bibr">2015</xref>; Verma &#x00026; Baranwal, <xref rid="CIT0055" ref-type="bibr">1983</xref>). Further, withanolide A from <italic>Withania somnifera</italic> has shown the highest binding affinity with S-protein and ACE-2 receptor. The active constituents of ayurvedic herb <italic>W. somnifera</italic> have shown promising anti-influenza properties by targeting neuraminidase of H1N1 influenza (Cai et al., <xref rid="CIT0005" ref-type="bibr">2015</xref>). AYUSH Ministry of Health, India, has further recommended the use of the aqueous extract of this plant as a preventive and prophylactic for treating COVID-19. Withametelin, from the <italic>Datura innoxia</italic> plant, has shown a better binding affinity against M<sup>pro</sup>, S-protein and ACE2. However, the pharmacological analysis revealed its toxicity to health. Instead, daturaolone, another compound from <italic>D. innoxia,</italic> have shown lower toxicity and higher HIA with potent anti-viral and anti-inflammatory activities. Overall, the selected medicinal plant bioactives can be further developed and assessed as phytoformulations against SARS-CoV-2 infection.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SM6846"><caption><title>Supplemental Material</title></caption><media xlink:href="TBSD_A_1842246_SM6846.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="SM5488"><caption><title>S6_ACE2_Taraxerol.mp4</title></caption><media xlink:href="TBSD_A_1842246_SM5488.mp4"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="SM5487"><caption><title>S5_ACE2_Nelfinavir.mp4</title></caption><media xlink:href="TBSD_A_1842246_SM5487.mp4"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="SM5486"><caption><title>S4_S-protein_tara_Taraxerol.mp4</title></caption><media xlink:href="TBSD_A_1842246_SM5486.mp4"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="SM5485"><caption><title>S3_S-protein_Nelfinavir.mp4</title></caption><media xlink:href="TBSD_A_1842246_SM5485.mp4"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="SM5484"><caption><title>S2_MPro_WithanolideA.mp4</title></caption><media xlink:href="TBSD_A_1842246_SM5484.mp4"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="SM5483"><caption><title>S1_MPro_Nelfinavir.mp4</title></caption><media xlink:href="TBSD_A_1842246_SM5483.mp4"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="SM5482"><caption><title>Supplementary_figures_S1-S9.pptx</title></caption><media xlink:href="TBSD_A_1842246_SM5482.pptx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><title>Acknowledgments</title><p>CSIR-CFTRI for the support and infrastructure facility. We thank Dr. Laskowski (The European Bioinformatics Institute (EMBL-EBI, Cambridgeshire, UK) for his valuable suggestions and providing customized LigPlot program. We thank Professor David A. Case (Rutgers University, NJ, USA) for providing access to the latest AMBER20 software.</p></ack><sec id="S0005" disp-level="1" sec-type="COI-statement"><title>Disclosure statement</title><p>No potential conflict of interest was reported by the authors.</p></sec><ref-list><title>References</title><ref id="CIT0001"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andersen</surname><given-names>K. G.</given-names></name>, <name name-style="western"><surname>Rambaut</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Lipkin</surname><given-names>W. I.</given-names></name>, <name name-style="western"><surname>Holmes</surname><given-names>E. C.</given-names></name>, &#x00026; <name name-style="western"><surname>Garry</surname><given-names>R. F.</given-names></name></person-group> (<year>2020</year>). <article-title>The proximal origin of SARS-CoV-2</article-title>. <source><italic toggle="yes">Nature Medicine</italic></source>, (<issue>4</issue>), <fpage>450</fpage>&#x02013;<lpage>452</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-020-0820-9</pub-id></mixed-citation></ref><ref id="CIT0002"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beigel</surname><given-names>J. H.</given-names></name>, <name name-style="western"><surname>Tomashek</surname><given-names>K. M.</given-names></name>, <name name-style="western"><surname>Dodd</surname><given-names>L. E.</given-names></name>, <name name-style="western"><surname>Mehta</surname><given-names>A. K.</given-names></name>, <name name-style="western"><surname>Zingman</surname><given-names>B. S.</given-names></name>, <name name-style="western"><surname>Kalil</surname><given-names>A. C.</given-names></name>, <name name-style="western"><surname>Hohmann</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Chu</surname><given-names>H. Y.</given-names></name>, <name name-style="western"><surname>Luetkemeyer</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Kline</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Lopez de Castilla</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Finberg</surname><given-names>R. W.</given-names></name>, <name name-style="western"><surname>Dierberg</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Tapson</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Hsieh</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Patterson</surname><given-names>T. F.</given-names></name>, <name name-style="western"><surname>Paredes</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Sweeney</surname><given-names>D. A.</given-names></name>, <name name-style="western"><surname>Short</surname><given-names>W. R.</given-names></name>, &#x02026; <name name-style="western"><surname>Lane</surname><given-names>H. C.</given-names></name></person-group> (<year>2020</year>). <article-title>Remdesivir for the treatment of Covid-19 &#x02014; Preliminary report</article-title>. <source><italic toggle="yes">New England Journal of Medicine</italic></source>, NEJMoa2007. PMID: 32445440. <pub-id pub-id-type="doi">10.1056/nejmoa2007764</pub-id></mixed-citation></ref><ref id="CIT0003"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhardwaj</surname><given-names>V. K.</given-names></name>, <name name-style="western"><surname>Singh</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Sharma</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Rajendran</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Purohit</surname><given-names>R.</given-names></name>, &#x00026; <name name-style="western"><surname>Kumar</surname><given-names>S.</given-names></name></person-group> (<year>2020</year>). <article-title>Identification of bioactive molecules from tea plant as SARS-CoV-2 main protease inhibitors</article-title>. <source><italic toggle="yes">Journal of Biomolecular Structure and Dynamics</italic></source>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1766572</pub-id></mixed-citation></ref><ref id="CIT0004"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonow</surname><given-names>R. O.</given-names></name>, <name name-style="western"><surname>Fonarow</surname><given-names>G. C.</given-names></name>, <name name-style="western"><surname>O'Gara</surname><given-names>P. T.</given-names></name>, &#x00026; <name name-style="western"><surname>Yancy</surname><given-names>C. W.</given-names></name></person-group> (<year>2020</year>). <article-title>Association of coronavirus disease 2019 (COVID-19) with myocardial injury and mortality</article-title>. <source><italic toggle="yes">JAMA Cardiology</italic></source>, (<issue>7</issue>), <fpage>751</fpage>&#x02013;<lpage>753</lpage>. <pub-id pub-id-type="doi">10.1001/jamacardio.2020.1105</pub-id><pub-id pub-id-type="pmid">32219362</pub-id></mixed-citation></ref><ref id="CIT0005"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cai</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Tang</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Fu</surname><given-names>X.</given-names></name>, &#x00026; <name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name></person-group> (<year>2015</year>). <article-title>Promising anti-influenza properties of active constituent of <italic>Withania somnifera</italic> Ayurvedic herb in targeting neuraminidase of H1N1 influenza: Computational study</article-title>. <source><italic toggle="yes">Cell Biochemistry and Biophysics</italic></source>, (<issue>3</issue>), <fpage>727</fpage>&#x02013;<lpage>739</lpage>. <pub-id pub-id-type="doi">10.1007/s12013-015-0524-9</pub-id><pub-id pub-id-type="pmid">25627548</pub-id></mixed-citation></ref><ref id="CIT0006"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Case</surname><given-names>D. A.</given-names></name>, <name name-style="western"><surname>Belfon</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Ben-Shalom</surname><given-names>I. Y.</given-names></name>, <name name-style="western"><surname>Brozell</surname><given-names>S. R.</given-names></name>, <name name-style="western"><surname>Cerutti</surname><given-names>D. S.</given-names></name>, <name name-style="western"><surname>Cheatham</surname><given-names>T. E.</given-names><suffix>III</suffix></name>, <name name-style="western"><surname>Cruzeiro</surname><given-names>V. W. D.</given-names></name>, <name name-style="western"><surname>Darden</surname><given-names>T. A.</given-names></name>, <name name-style="western"><surname>Duke</surname><given-names>R. E.</given-names></name>, <name name-style="western"><surname>Giambasu</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Gilson</surname><given-names>M. K.</given-names></name>, <name name-style="western"><surname>Gohlke</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Goetz</surname><given-names>A. W.</given-names></name>, <name name-style="western"><surname>Harris</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Izadi</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Izmailov</surname><given-names>S. A.</given-names></name>, <name name-style="western"><surname>Kasavajhala</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Kovalenko</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Krasny</surname><given-names>R.</given-names></name>, &#x02026; <name name-style="western"><surname>Kollman</surname><given-names>P. A.</given-names></name></person-group> (<year>2020</year>). <source>AMBER 2020</source>. <publisher-name>University of California</publisher-name>.</mixed-citation></ref><ref id="CIT0007"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>J. L.</given-names></name>, <name name-style="western"><surname>Blanc</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Stoddart</surname><given-names>C. A.</given-names></name>, <name name-style="western"><surname>Bogan</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Rozhon</surname><given-names>E. J.</given-names></name>, <name name-style="western"><surname>Parkinson</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Ye</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Cooper</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Balick</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Nanakorn</surname><given-names>W.</given-names></name>, &#x00026; <name name-style="western"><surname>Kernan</surname><given-names>M. R.</given-names></name></person-group> (<year>1998</year>). <article-title>New iridoids from the medicinal plant Barleria prionitis with potent activity against respiratory syncytial virus</article-title>. <source><italic toggle="yes">Journal of Natural Products</italic></source>, (<issue>10</issue>), <fpage>1295</fpage>&#x02013;<lpage>1297</lpage>. <pub-id pub-id-type="doi">10.1021/np980086y</pub-id><pub-id pub-id-type="pmid">9784173</pub-id></mixed-citation></ref><ref id="CIT0008"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corn&#x000e9;lio Favarin</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Robison De Oliveira</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Jose Freire De Oliveira</surname><given-names>C.</given-names></name>, &#x00026; <name name-style="western"><surname>De Paula Rogerio</surname><given-names>A.</given-names></name></person-group> (<year>2013</year>). <article-title>Potential effects of medicinal plants and secondary metabolites on acute lung injury</article-title>. <source><italic toggle="yes">BioMed Research International</italic></source>, , <fpage>576479</fpage>
<pub-id pub-id-type="doi">10.1155/2013/576479</pub-id><pub-id pub-id-type="pmid">24224172</pub-id></mixed-citation></ref><ref id="CIT0009"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daina</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Michielin</surname><given-names>O.</given-names></name>, &#x00026; <name name-style="western"><surname>Zoete</surname><given-names>V.</given-names></name></person-group> (<year>2017</year>). <article-title>SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules</article-title>. <source><italic toggle="yes">Scientific Reports</italic></source>, , <fpage>42717</fpage>
<pub-id pub-id-type="doi">10.1038/srep42717</pub-id><pub-id pub-id-type="pmid">28256516</pub-id></mixed-citation></ref><ref id="CIT0010"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>N. N.</given-names></name>, <name name-style="western"><surname>Yao</surname><given-names>Z. J.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Cheng</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Ouyang</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>A. P.</given-names></name>, &#x00026; <name name-style="western"><surname>Cao</surname><given-names>D. S.</given-names></name></person-group> (<year>2018</year>). <article-title>Admetlab: A platform for systematic ADMET evaluation based on a comprehensively collected ADMET database</article-title>. <source><italic toggle="yes">Journal of Cheminformatics</italic></source>, (<issue>1</issue>), <fpage>29</fpage>
<pub-id pub-id-type="doi">10.1186/s13321-018-0283-x</pub-id><pub-id pub-id-type="pmid">29943074</pub-id></mixed-citation></ref><ref id="CIT0011"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Drwal</surname><given-names>M. N.</given-names></name>, <name name-style="western"><surname>Banerjee</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Dunkel</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Wettig</surname><given-names>M. R.</given-names></name>, &#x00026; <name name-style="western"><surname>Preissner</surname><given-names>R.</given-names></name></person-group> (<year>2014</year>). <article-title>ProTox: A web server for the in silico prediction of rodent oral toxicity</article-title>. <source><italic toggle="yes">Nucleic Acids Research</italic></source>, (<issue>Web Server issue</issue>), <fpage>W53</fpage>&#x02013;<lpage>W58</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gku401</pub-id><pub-id pub-id-type="pmid">24838562</pub-id></mixed-citation></ref><ref id="CIT0012"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ertl</surname><given-names>P.</given-names></name>, &#x00026; <name name-style="western"><surname>Schuffenhauer</surname><given-names>A.</given-names></name></person-group> (<year>2009</year>). <article-title>Estimation of synthetic accessibility score of drug-like molecules based on molecular complexity and fragment contributions</article-title>. <source><italic toggle="yes">Journal of Cheminformatics</italic></source>, (<issue>1</issue>), <fpage>8</fpage>
<pub-id pub-id-type="doi">10.1186/1758-2946-1-8</pub-id><pub-id pub-id-type="pmid">20298526</pub-id></mixed-citation></ref><ref id="CIT0013"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Estari</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Venkanna</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Sripriya</surname><given-names>D.</given-names></name>, &#x00026; <name name-style="western"><surname>Lalitha</surname><given-names>R.</given-names></name></person-group> (<year>2012</year>). <article-title>Human immunodeficiency virus (HIV-1) reverse transcriptase inhibitory activity of phyllanthus emblica plant extract</article-title>. <source><italic toggle="yes">Biology and Medicine</italic></source>, (<issue>4</issue>), <fpage>178</fpage>
<pub-id pub-id-type="doi">10.4172/0974-8369.1000175</pub-id></mixed-citation></ref><ref id="CIT0014"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Filimonov</surname><given-names>D. A.</given-names></name>, <name name-style="western"><surname>Lagunin</surname><given-names>A. A.</given-names></name>, <name name-style="western"><surname>Gloriozova</surname><given-names>T. A.</given-names></name>, <name name-style="western"><surname>Rudik</surname><given-names>A. V.</given-names></name>, <name name-style="western"><surname>Druzhilovskii</surname><given-names>D. S.</given-names></name>, <name name-style="western"><surname>Pogodin</surname><given-names>P. V.</given-names></name>, &#x00026; <name name-style="western"><surname>Poroikov</surname><given-names>V. V.</given-names></name></person-group> (<year>2014</year>). <article-title>Prediction of the biological activity spectra of organic compounds using the pass online web resource</article-title>. <source><italic toggle="yes">Chemistry of Heterocyclic Compounds</italic></source>, (<issue>3</issue>), <fpage>444</fpage>&#x02013;<lpage>457</lpage>. <pub-id pub-id-type="doi">10.1007/s10593-014-1496-1</pub-id></mixed-citation></ref><ref id="CIT0015"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fiore</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Eisenhut</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Krausse</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Ragazzi</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Pellati</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Armanini</surname><given-names>D.</given-names></name>, &#x00026; <name name-style="western"><surname>Bielenberg</surname><given-names>J.</given-names></name></person-group> (<year>2008</year>). <article-title>Antiviral effects of Glycyrrhiza species</article-title>. <source><italic toggle="yes">Phytotherapy Research</italic></source>, (<issue>2</issue>), <fpage>141</fpage>&#x02013;<lpage>148</lpage>. <pub-id pub-id-type="doi">10.1002/ptr.2295</pub-id><pub-id pub-id-type="pmid">17886224</pub-id></mixed-citation></ref><ref id="CIT0016"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ganjhu</surname><given-names>R. K.</given-names></name>, <name name-style="western"><surname>Mudgal</surname><given-names>P. P.</given-names></name>, <name name-style="western"><surname>Maity</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Dowarha</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Devadiga</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Nag</surname><given-names>S.</given-names></name>, &#x00026; <name name-style="western"><surname>Arunkumar</surname><given-names>G.</given-names></name></person-group> (<year>2015</year>). <article-title>Herbal plants and plant preparations as remedial approach for viral diseases</article-title>. <source>Virusdisease</source>, (<issue>4</issue>), <fpage>225</fpage>&#x02013;<lpage>236</lpage>. <pub-id pub-id-type="doi">10.1007/s13337-015-0276-6</pub-id><pub-id pub-id-type="pmid">26645032</pub-id></mixed-citation></ref><ref id="CIT0017"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glue</surname><given-names>P.</given-names></name>, &#x00026; <name name-style="western"><surname>Clement</surname><given-names>R. P.</given-names></name></person-group> (<year>1999</year>). <article-title>Cytochrome P450 enzymes and drug metabolism - Basic concepts and methods of assessment</article-title>. <source><italic toggle="yes">Cellular and Molecular Neurobiology</italic></source>, (<issue>3</issue>), <fpage>309</fpage>&#x02013;<lpage>323</lpage>. <ext-link ext-link-type="uri" xlink:href="https://doi.org/1006993631057">https://doi.org/1006993631057</ext-link><pub-id pub-id-type="pmid">10319190</pub-id></mixed-citation></ref><ref id="CIT0018"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goyal</surname><given-names>B.</given-names></name>, &#x00026; <name name-style="western"><surname>Goyal</surname><given-names>D.</given-names></name></person-group> (<year>2020</year>). <article-title>Targeting the dimerization of the main protease of coronaviruses: A potential broad-spectrum therapeutic strategy</article-title>. <source><italic toggle="yes">ACS Combinatorial Science</italic></source>, (<issue>6</issue>), <fpage>297</fpage>&#x02013;<lpage>305</lpage>. <pub-id pub-id-type="doi">10.1021/acscombsci.0c00058</pub-id><pub-id pub-id-type="pmid">32402186</pub-id></mixed-citation></ref><ref id="CIT0019"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hepcy Kalarani</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Dinakar</surname><given-names>A.</given-names></name>, &#x00026; <name name-style="western"><surname>Senthilkumar</surname><given-names>N.</given-names></name></person-group> (<year>2012</year>). <article-title>Antidiabetic, analgesic and anti-inflammatory activity of aqueous extracts of stem and leaves of <italic>Alangium salvifolium</italic> and <italic>Pavonia zeylanica</italic></article-title>. <source><italic toggle="yes">International Journal of Drug Development and Research</italic></source>, , <fpage>298</fpage>&#x02013;<lpage>306</lpage>.</mixed-citation></ref><ref id="CIT0020"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hong</surname><given-names>J. F.</given-names></name>, <name name-style="western"><surname>Song</surname><given-names>Y. F.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Zheng</surname><given-names>Z. C.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>H. J.</given-names></name>, &#x00026; <name name-style="western"><surname>Wang</surname><given-names>S. S.</given-names></name></person-group> (<year>2016</year>). <article-title>Anticancer activity of taraxerol acetate in human glioblastoma cells and a mouse xenograft model via induction of autophagy and apoptotic cell death, cell cycle arrest and inhibition of cell migration</article-title>. <source><italic toggle="yes">Molecular Medicine Reports</italic></source>, (<issue>6</issue>), <fpage>4541</fpage>&#x02013;<lpage>4548</lpage>. <pub-id pub-id-type="doi">10.3892/mmr.2016.5105</pub-id><pub-id pub-id-type="pmid">27081915</pub-id></mixed-citation></ref><ref id="CIT0021"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huo</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Ren</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Duyvesteyn</surname><given-names>H. M. E.</given-names></name>, <name name-style="western"><surname>Ginn</surname><given-names>H. M.</given-names></name>, <name name-style="western"><surname>Carrique</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Malinauskas</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Ruza</surname><given-names>R. R.</given-names></name>, <name name-style="western"><surname>Shah</surname><given-names>P. N. M.</given-names></name>, <name name-style="western"><surname>Tan</surname><given-names>T. K.</given-names></name>, <name name-style="western"><surname>Rijal</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Coombes</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Bewley</surname><given-names>K. R.</given-names></name>, <name name-style="western"><surname>Tree</surname><given-names>J. A.</given-names></name>, <name name-style="western"><surname>Radecke</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Paterson</surname><given-names>N. G.</given-names></name>, <name name-style="western"><surname>Supasa</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Mongkolsapaya</surname><given-names>J.</given-names></name>, &#x02026; <name name-style="western"><surname>Stuart</surname><given-names>D. I.</given-names></name></person-group> (<year>2020</year>). <article-title>Neutralization of SARS-CoV-2 by destruction of the prefusion spike</article-title>. <source><italic toggle="yes">Cell Host &#x00026; Microbe</italic></source>, (<issue>3</issue>), <fpage>445</fpage>&#x02013;<lpage>454.e6</lpage>. <pub-id pub-id-type="doi">10.1016/j.chom.2020.06.010</pub-id><pub-id pub-id-type="pmid">32585135</pub-id></mixed-citation></ref><ref id="CIT0022"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Du</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Deng</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Peng</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Duan</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>You</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name>, &#x02026; <name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name></person-group> (<year>2020</year>). <article-title>Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors</article-title>. <source>Nature</source>, (<issue>7811</issue>), <fpage>289</fpage>&#x02013;<lpage>293</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2223-y</pub-id><pub-id pub-id-type="pmid">32272481</pub-id></mixed-citation></ref><ref id="CIT0023"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamath</surname><given-names>P. R.</given-names></name>, <name name-style="western"><surname>Sunil</surname><given-names>D.</given-names></name>, &#x00026; <name name-style="western"><surname>Ajees</surname><given-names>A. A.</given-names></name></person-group> (<year>2016</year>). <article-title>Synthesis of indole&#x02013;quinoline&#x02013;oxadiazoles: Their anticancer potential and computational tubulin binding studies</article-title>. <source><italic toggle="yes">Research on Chemical Intermediates</italic></source>, (<issue>6</issue>), <fpage>5899</fpage>&#x02013;<lpage>5914</lpage>. <pub-id pub-id-type="doi">10.1007/s11164-015-2412-8</pub-id></mixed-citation></ref><ref id="CIT0024"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamath</surname><given-names>P. R.</given-names></name>, <name name-style="western"><surname>Sunil</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Ajees</surname><given-names>A. A.</given-names></name>, <name name-style="western"><surname>Pai</surname><given-names>K. S. R.</given-names></name>, &#x00026; <name name-style="western"><surname>Das</surname><given-names>S.</given-names></name></person-group> (<year>2015</year>). <article-title>Some new indole-coumarin hybrids; Synthesis, anticancer and Bcl-2 docking studies</article-title>. <source><italic toggle="yes">Bioorganic Chemistry</italic></source>, , <fpage>101</fpage>&#x02013;<lpage>109</lpage>. <pub-id pub-id-type="doi">10.1016/j.bioorg.2015.10.001</pub-id><pub-id pub-id-type="pmid">26469742</pub-id></mixed-citation></ref><ref id="CIT0025"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kesharwani</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Polachira</surname><given-names>S. K.</given-names></name>, <name name-style="western"><surname>Nair</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Agarwal</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Mishra</surname><given-names>N. N.</given-names></name>, &#x00026; <name name-style="western"><surname>Gupta</surname><given-names>S. K.</given-names></name></person-group> (<year>2017</year>). <article-title>Anti-HSV-2 activity of <italic>Terminalia chebula</italic> Retz extract and its constituents, chebulagic and chebulinic acids</article-title>. <source><italic toggle="yes">BMC Complementary and Alternative Medicine</italic></source>, (<issue>1</issue>), <fpage>110</fpage>
<pub-id pub-id-type="doi">10.1186/s12906-017-1620-8</pub-id><pub-id pub-id-type="pmid">28196487</pub-id></mixed-citation></ref><ref id="CIT0026"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Cheng</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Gindulyte</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>He</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>He</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Shoemaker</surname><given-names>B. A.</given-names></name>, <name name-style="western"><surname>Thiessen</surname><given-names>P. A.</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Zaslavsky</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name>, &#x00026; <name name-style="western"><surname>Bolton</surname><given-names>E. E.</given-names></name></person-group> (<year>2019</year>). <article-title>PubChem 2019 update: Improved access to chemical data</article-title>. <source><italic toggle="yes">Nucleic Acids Research</italic></source>, (<issue>D1</issue>), <fpage>D1102</fpage>&#x02013;<lpage>D1109</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gky1033</pub-id><pub-id pub-id-type="pmid">30371825</pub-id></mixed-citation></ref><ref id="CIT0027"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lan</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Ge</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Shan</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Fan</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Shi</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name>, &#x00026; <name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name></person-group> (<year>2020</year>). <article-title>Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor</article-title>. <source>Nature</source>, (<issue>7807</issue>), <fpage>215</fpage>&#x02013;<lpage>220</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2180-5</pub-id></mixed-citation></ref><ref id="CIT0028"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laskowski</surname><given-names>R. A.</given-names></name>, &#x00026; <name name-style="western"><surname>Swindells</surname><given-names>M. B.</given-names></name></person-group> (<year>2011</year>). <article-title>LigPlot+: Multiple ligand-protein interaction diagrams for drug discovery</article-title>. <source><italic toggle="yes">Journal of Chemical Information and Modeling</italic></source>, (<issue>10</issue>), <fpage>2778</fpage>&#x02013;<lpage>2786</lpage>. <pub-id pub-id-type="doi">10.1021/ci200227u</pub-id><pub-id pub-id-type="pmid">21919503</pub-id></mixed-citation></ref><ref id="CIT0029"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Limban</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Nu&#x00163;&#x00103;</surname><given-names>D. C.</given-names></name>, <name name-style="western"><surname>Chiri&#x00163;&#x00103;</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Negre&#x00219;</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Arsene</surname><given-names>A. L.</given-names></name>, <name name-style="western"><surname>Goumenou</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Karakitsios</surname><given-names>S. P.</given-names></name>, <name name-style="western"><surname>Tsatsakis</surname><given-names>A. M.</given-names></name>, &#x00026; <name name-style="western"><surname>Sarigiannis</surname><given-names>D. A.</given-names></name></person-group> (<year>2018</year>). <article-title>The use of structural alerts to avoid the toxicity of pharmaceuticals</article-title>. <source>Toxicology <italic toggle="yes">Reports</italic></source>, , <fpage>943</fpage>&#x02013;<lpage>953</lpage>. <pub-id pub-id-type="doi">10.1016/j.toxrep.2018.08.017</pub-id><pub-id pub-id-type="pmid">30258789</pub-id></mixed-citation></ref><ref id="CIT0030"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liperoti</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Vetrano</surname><given-names>D. L.</given-names></name>, <name name-style="western"><surname>Bernabei</surname><given-names>R.</given-names></name>, &#x00026; <name name-style="western"><surname>Onder</surname><given-names>G.</given-names></name></person-group> (<year>2017</year>). <article-title>Herbal medications in cardiovascular medicine</article-title>. <source><italic toggle="yes">Journal of the American College of Cardiology</italic></source>, (<issue>9</issue>), <fpage>1188</fpage>&#x02013;<lpage>1199</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2016.11.078</pub-id><pub-id pub-id-type="pmid">28254182</pub-id></mixed-citation></ref><ref id="CIT0031"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lipinski</surname><given-names>C. A.</given-names></name></person-group> (<year>2004</year>). <article-title>Lead- and drug-like compounds: The rule-of-five revolution</article-title>. <source><italic toggle="yes">Drug Discovery Today: Technologies</italic></source>, (<issue>4</issue>), <fpage>337</fpage>&#x02013;<lpage>341</lpage>. <pub-id pub-id-type="doi">10.1016/j.ddtec.2004.11.007</pub-id><pub-id pub-id-type="pmid">24981612</pub-id></mixed-citation></ref><ref id="CIT0032"><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>MarvinSketch</collab></person-group> (<year>n.d</year>). <source>MarvinSketch was used to convert chemical structures from 2D to 3D</source>. <publisher-name>ChemAxon</publisher-name>
<ext-link ext-link-type="uri" xlink:href="https://www.chemaxon.com">https://www.chemaxon.com</ext-link>.</mixed-citation></ref><ref id="CIT0033"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Merad</surname><given-names>M.</given-names></name>, &#x00026; <name name-style="western"><surname>Martin</surname><given-names>J. C.</given-names></name></person-group> (<year>2020</year>). <article-title>Pathological inflammation in patients with COVID-19: A key role for monocytes and macrophages</article-title>. <source><italic toggle="yes">Nature Reviews: Immunology</italic></source>, (<issue>6</issue>), <fpage>355</fpage>&#x02013;<lpage>362</lpage>. <pub-id pub-id-type="doi">10.1038/s41577-020-0331-4</pub-id></mixed-citation></ref><ref id="CIT0034"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mishra</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Dixit</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Ratan</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Srivastava</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Trivedi</surname><given-names>S.</given-names></name>, &#x00026; <name name-style="western"><surname>Srivastava</surname><given-names>Y. K.</given-names></name></person-group> (<year>2018</year>). <article-title>Identification and in silico screening of biologically active secondary metabolites isolated from Trichoderma harzianum</article-title>. <source><italic toggle="yes">Annals of Phytomedicine: An International Journal</italic></source>, (<issue>1</issue>), <fpage>78</fpage>&#x02013;<lpage>86</lpage>. <pub-id pub-id-type="doi">10.21276/ap.2018.7.1.9</pub-id></mixed-citation></ref><ref id="CIT0035"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morris</surname><given-names>G. M.</given-names></name>, <name name-style="western"><surname>Huey</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Lindstrom</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Scanner</surname><given-names>M. F.</given-names></name>, <name name-style="western"><surname>Belew</surname><given-names>R. S.</given-names></name>, <name name-style="western"><surname>Goodsell</surname><given-names>D. S.</given-names></name>, &#x00026; <name name-style="western"><surname>Olson</surname><given-names>A. J.</given-names></name></person-group> (<year>2009</year>). <article-title>AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility</article-title>. <source><italic toggle="yes">Journal of Computational Chemistry</italic></source>, (<issue>16</issue>), <fpage>2785</fpage>&#x02013;<lpage>2791</lpage>. <pub-id pub-id-type="doi">10.1002/jcc.21256</pub-id><pub-id pub-id-type="pmid">19399780</pub-id></mixed-citation></ref><ref id="CIT0036"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mukhtar</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Arshad</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Ahmad</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Pomerantz</surname><given-names>R. J.</given-names></name>, <name name-style="western"><surname>Wigdahl</surname><given-names>B.</given-names></name>, &#x00026; <name name-style="western"><surname>Parveen</surname><given-names>Z.</given-names></name></person-group> (<year>2008</year>). <article-title>Antiviral potentials of medicinal plants</article-title>. <source><italic toggle="yes">Virus Research</italic></source>, (<issue>2</issue>), <fpage>111</fpage>&#x02013;<lpage>120</lpage>. <pub-id pub-id-type="doi">10.1016/j.virusres.2007.09.008</pub-id></mixed-citation></ref><ref id="CIT0037"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nagarkar</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Nirmal</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Narkhede</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Kuvalekar</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Kulkarni</surname><given-names>O.</given-names></name>, <name name-style="western"><surname>Harsulkar</surname><given-names>A.</given-names></name>, &#x00026; <name name-style="western"><surname>Jagtap</surname><given-names>S.</given-names></name></person-group> (<year>2013</year>). <article-title>Comparative evaluation of anti-inflammatory potential of medicinally important plants</article-title>. <source><italic toggle="yes">International Journal of Pharmacy and Pharmaceutical Sciences</italic></source>, , <fpage>239</fpage>&#x02013;<lpage>243</lpage>.</mixed-citation></ref><ref id="CIT0038"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Naidoo</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Roy</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Kar</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Mutanda</surname><given-names>T.</given-names></name>, &#x00026; <name name-style="western"><surname>Anandraj</surname><given-names>A.</given-names></name></person-group> (<year>2020</year>). <article-title>Cyanobacterial metabolites as promising drug leads against the Mpro and PLpro of SARS-CoV-2: An in silico analysis</article-title>. <source><italic toggle="yes">Journal of Biomolecular Structure and Dynamics</italic></source>, <fpage>1</fpage>&#x02013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1794972</pub-id></mixed-citation></ref><ref id="CIT0039"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#x02019;Boyle</surname><given-names>N. M.</given-names></name>, <name name-style="western"><surname>Banck</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>James</surname><given-names>C. A.</given-names></name>, <name name-style="western"><surname>Morley</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Vandermeersch</surname><given-names>T.</given-names></name>, &#x00026; <name name-style="western"><surname>Hutchison</surname><given-names>G. R.</given-names></name></person-group> (<year>2011</year>). <article-title>Open Babel: An open chemical toolbox</article-title>. <source><italic toggle="yes">Journal of Cheminformatics</italic></source>, (<issue>1</issue>), <fpage>33</fpage>
<pub-id pub-id-type="doi">10.1186/1758-2946-3-33</pub-id><pub-id pub-id-type="pmid">21982300</pub-id></mixed-citation></ref><ref id="CIT0040"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Onawole</surname><given-names>A. T.</given-names></name>, <name name-style="western"><surname>Kolapo</surname><given-names>T. U.</given-names></name>, <name name-style="western"><surname>Sulaiman</surname><given-names>K. O.</given-names></name>, &#x00026; <name name-style="western"><surname>Adegoke</surname><given-names>R. O.</given-names></name></person-group> (<year>2018</year>). <article-title>Structure based virtual screening of the Ebola virus trimeric glycoprotein using consensus scoring</article-title>. <source><italic toggle="yes">Computational Biology and Chemistry</italic></source>, , <fpage>170</fpage>&#x02013;<lpage>180</lpage>. <pub-id pub-id-type="doi">10.1016/j.compbiolchem.2017.11.006</pub-id></mixed-citation></ref><ref id="CIT0041"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pruthvish</surname><given-names>R.</given-names></name>, &#x00026; <name name-style="western"><surname>Gopinatha</surname><given-names>R. P.</given-names></name></person-group> (<year>2018</year>). <article-title>Antiviral prospective of Tinospora cordifolia on HSV-1</article-title>. <source><italic toggle="yes">International Journal of Current Microbiology and Applied Sciences</italic></source>, (<issue>1</issue>), <fpage>3617</fpage>&#x02013;<lpage>3624</lpage>. <pub-id pub-id-type="doi">10.20546/ijcmas.2018.701.425</pub-id></mixed-citation></ref><ref id="CIT0042"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Radchenko</surname><given-names>E. V.</given-names></name>, <name name-style="western"><surname>Dyabina</surname><given-names>A. S.</given-names></name>, <name name-style="western"><surname>Palyulin</surname><given-names>V. A.</given-names></name>, &#x00026; <name name-style="western"><surname>Zefirov</surname><given-names>N. S.</given-names></name></person-group> (<year>2016</year>). <article-title>Prediction of human intestinal absorption of drug compounds</article-title>. <source><italic toggle="yes">Russian Chemical Bulletin</italic></source>, (<issue>2</issue>), <fpage>576</fpage>&#x02013;<lpage>580</lpage>. <pub-id pub-id-type="doi">10.1007/s11172-016-1340-0</pub-id></mixed-citation></ref><ref id="CIT0043"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodr&#x000ed;guez-Morales</surname><given-names>A. J.</given-names></name>, <name name-style="western"><surname>MacGregor</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Kanagarajah</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Patel</surname><given-names>D.</given-names></name>, &#x00026; <name name-style="western"><surname>Schlagenhauf</surname><given-names>P.</given-names></name></person-group> (<year>2020</year>). <article-title>Going global - Travel and the 2019 novel coronavirus</article-title>. <source><italic toggle="yes">Travel Medicine and Infectious Disease</italic></source>, , <fpage>101578</fpage>
<pub-id pub-id-type="doi">10.1016/j.tmaid.2020.101578</pub-id><pub-id pub-id-type="pmid">32044389</pub-id></mixed-citation></ref><ref id="CIT0044"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roe</surname><given-names>D. R.</given-names></name>, &#x00026; <name name-style="western"><surname>Cheatham</surname><given-names>T. E.</given-names></name></person-group> (<year>2013</year>). <article-title>PTRAJ and CPPTRAJ: Software for processing and analysis of molecular dynamics trajectory data</article-title>. <source><italic toggle="yes">Journal of Chemical Theory and Computation</italic></source>, (<issue>7</issue>), <fpage>3084</fpage>&#x02013;<lpage>3095</lpage>. <pub-id pub-id-type="doi">10.1021/ct400341p</pub-id><pub-id pub-id-type="pmid">26583988</pub-id></mixed-citation></ref><ref id="CIT0045"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roy</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Mukherjee</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Pawar</surname><given-names>S.</given-names></name>, &#x00026; <name name-style="western"><surname>Chowdhary</surname><given-names>A.</given-names></name></person-group> (<year>2016</year>). <article-title>Evaluation of in vitro antiviral activity of <italic>Datura metel</italic> Linn. against rabies virus</article-title>. <source><italic toggle="yes">Pharmacognosy Research</italic></source>, (<issue>4</issue>), <fpage>265</fpage>&#x02013;<lpage>269</lpage>. <pub-id pub-id-type="doi">10.4103/0974-8490.188874</pub-id><pub-id pub-id-type="pmid">27695266</pub-id></mixed-citation></ref><ref id="CIT0046"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salam</surname><given-names>A. A. A.</given-names></name>, <name name-style="western"><surname>Nayek</surname><given-names>U.</given-names></name>, &#x00026; <name name-style="western"><surname>Sunil</surname><given-names>D.</given-names></name></person-group> (<year>2018</year>). <article-title>Homology modeling and docking studies of Bcl-2 and Bcl-xL with small molecule inhibitors: Identification and functional studies</article-title>. <source><italic toggle="yes">Current Topics in Medicinal Chemistry</italic></source>, (<issue>31</issue>), <fpage>2633</fpage>&#x02013;<lpage>2663</lpage>. <pub-id pub-id-type="doi">10.2174/1568026619666190119144819</pub-id><pub-id pub-id-type="pmid">30659540</pub-id></mixed-citation></ref><ref id="CIT0047"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>S&#x000e8;ve</surname><given-names>P.</given-names></name>, &#x00026; <name name-style="western"><surname>Dumontet</surname><given-names>C.</given-names></name></person-group> (<year>2005</year>). <article-title>Chemoresistance in non-small cell lung cancer</article-title>. <source><italic toggle="yes">Current Medicinal Chemistry. Anti-Cancer Agents</italic></source>, (<issue>1</issue>), <fpage>73</fpage>&#x02013;<lpage>88</lpage>. <pub-id pub-id-type="doi">10.2174/1568011053352604</pub-id><pub-id pub-id-type="pmid">15720263</pub-id></mixed-citation></ref><ref id="CIT0048"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shahidul Alam</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Quader</surname><given-names>M. A.</given-names></name>, &#x00026; <name name-style="western"><surname>Rashid</surname><given-names>M. A.</given-names></name></person-group> (<year>2000</year>). <article-title>HIV-inhibitory diterpenoid from <italic>Anisomeles indica</italic></article-title>. <source>Fitoterapia</source>, (<issue>5</issue>), <fpage>574</fpage>&#x02013;<lpage>576</lpage>. <pub-id pub-id-type="doi">10.1016/S0367-326X</pub-id>(00)00197-0<pub-id pub-id-type="pmid">11449512</pub-id></mixed-citation></ref><ref id="CIT0049"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shang</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Ye</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Shi</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Wan</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Luo</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Aihara</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Geng</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Auerbach</surname><given-names>A.</given-names></name>, &#x00026; <name name-style="western"><surname>Li</surname><given-names>F.</given-names></name></person-group> (<year>2020</year>). <article-title>Structural basis of receptor recognition by SARS-CoV-2</article-title>. <source>Nature</source>, (<issue>7807</issue>), <fpage>221</fpage>&#x02013;<lpage>224</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2179-y</pub-id></mixed-citation></ref><ref id="CIT0050"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>K.</given-names></name>, &#x00026; <name name-style="western"><surname>Zafar</surname><given-names>R.</given-names></name></person-group> (<year>2015</year>). <article-title>Occurrence of taraxerol and taraxasterol in medicinal plants</article-title>. <source><italic toggle="yes">Pharmacognosy Reviews</italic></source>, (<issue>17</issue>), <fpage>19</fpage>
<pub-id pub-id-type="doi">10.4103/0973-7847.156317</pub-id><pub-id pub-id-type="pmid">26009688</pub-id></mixed-citation></ref><ref id="CIT0051"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Towler</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Staker</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Prasad</surname><given-names>S. G.</given-names></name>, <name name-style="western"><surname>Menon</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Parsons</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Ryan</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Fisher</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Williams</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Dales</surname><given-names>N. A.</given-names></name>, <name name-style="western"><surname>Patane</surname><given-names>M. A.</given-names></name>, &#x00026; <name name-style="western"><surname>Pantoliano</surname><given-names>M. W.</given-names></name></person-group> (<year>2004</year>). <article-title>ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis</article-title>. <source><italic toggle="yes">The Journal of Biological Chemistry</italic></source>, (<issue>17</issue>), <fpage>17996</fpage>&#x02013;<lpage>18007</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M311191200</pub-id><pub-id pub-id-type="pmid">14754895</pub-id></mixed-citation></ref><ref id="CIT0052"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trott</surname><given-names>O.</given-names></name>, &#x00026; <name name-style="western"><surname>Olson</surname><given-names>A. J.</given-names></name></person-group> (<year>2010</year>). <article-title>AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading</article-title>. <source><italic toggle="yes">Journal of Computational Chemistry</italic></source>, (<issue>2</issue>), <fpage>455</fpage>&#x02013;<lpage>461</lpage>. <pub-id pub-id-type="doi">10.1002/jcc.21334</pub-id><pub-id pub-id-type="pmid">19499576</pub-id></mixed-citation></ref><ref id="CIT0053"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veeramachaneni</surname><given-names>G. K.</given-names></name>, <name name-style="western"><surname>Thunuguntla</surname><given-names>V. B. S. C.</given-names></name>, <name name-style="western"><surname>Bobbillapati</surname><given-names>J.</given-names></name>, &#x00026; <name name-style="western"><surname>Bondili</surname><given-names>J. S.</given-names></name></person-group> (<year>2020</year>). <article-title>Structural and simulation analysis of hotspot residues interactions of SARS-CoV 2 with human ACE2 receptor</article-title>. <source><italic toggle="yes">Journal of Biomolecular Structure and Dynamics</italic></source>, <fpage>1</fpage>&#x02013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1773318</pub-id></mixed-citation></ref><ref id="CIT0054"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vellingiri</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Jayaramayya</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Iyer</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Narayanasamy</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Govindasamy</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Giridharan</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Ganesan</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Venugopal</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Venkatesan</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Ganesan</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Rajagopalan</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Rahman</surname><given-names>P. K. S. M.</given-names></name>, <name name-style="western"><surname>Cho</surname><given-names>S. G.</given-names></name>, <name name-style="western"><surname>Kumar</surname><given-names>N. S.</given-names></name>, &#x00026; <name name-style="western"><surname>Subramaniam</surname><given-names>M. D.</given-names></name></person-group> (<year>2020</year>). <article-title>COVID-19: A promising cure for the global panic</article-title>. <source><italic toggle="yes">The Science of the Total Environment</italic></source>, , <fpage>138277</fpage>
<pub-id pub-id-type="doi">10.1016/j.scitotenv.2020.138277</pub-id><pub-id pub-id-type="pmid">32278175</pub-id></mixed-citation></ref><ref id="CIT0055"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verma</surname><given-names>H. N.</given-names></name>, &#x00026; <name name-style="western"><surname>Baranwal</surname><given-names>V. K.</given-names></name></person-group> (<year>1983</year>). <article-title>Antiviral activity and the physical properties of the leaf extract of <italic>Chenopodium ambrosoides</italic> L</article-title>. <source><italic toggle="yes">Proceedings: Plant Sciences</italic></source>, (<issue>6</issue>), <fpage>461</fpage>&#x02013;<lpage>465</lpage>. <pub-id pub-id-type="doi">10.1007/BF03053019</pub-id></mixed-citation></ref><ref id="CIT0056"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verma</surname><given-names>H. N.</given-names></name>, <name name-style="western"><surname>Chowdhury</surname><given-names>B.</given-names></name>, &#x00026; <name name-style="western"><surname>Rastogi</surname><given-names>P.</given-names></name></person-group> (<year>1984</year>). <article-title>Antiviral activity in leaf extracts of different Clerodendrum species</article-title>. <source><italic toggle="yes">Journal of Plant Diseases and Protection</italic></source>, (<issue>1</issue>), <fpage>34</fpage>&#x02013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.2307/43382724</pub-id></mixed-citation></ref><ref id="CIT0057"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Xia</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name>, &#x00026; <name name-style="western"><surname>Zhou</surname><given-names>Q.</given-names></name></person-group> (<year>2020</year>). <article-title>Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2</article-title>. <source><italic toggle="yes">Science (New York, N.Y.)</italic></source>, (<issue>6485</issue>), <fpage>1444</fpage>&#x02013;<lpage>1448</lpage>. <pub-id pub-id-type="doi">10.1126/science.abb2762</pub-id></mixed-citation></ref><ref id="CIT0058"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Bai</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name>, &#x00026; <name name-style="western"><surname>L&#x000fc;</surname><given-names>C.</given-names></name></person-group> (<year>2013</year>). <article-title>Taraxerol inhibits LPS-induced inflammatory responses through suppression of TAK1 and Akt activation</article-title>. <source><italic toggle="yes">International Immunopharmacology</italic></source>, (<issue>2</issue>), <fpage>316</fpage>&#x02013;<lpage>324</lpage>. <pub-id pub-id-type="doi">10.1016/j.intimp.2012.12.032</pub-id><pub-id pub-id-type="pmid">23333629</pub-id></mixed-citation></ref><ref id="CIT0059"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yi</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Ye</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Ding</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Gu</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Qu</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Shi</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Ling</surname><given-names>Z.</given-names></name>, &#x00026; <name name-style="western"><surname>Sun</surname><given-names>B.</given-names></name></person-group> (<year>2020</year>). <article-title>Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies</article-title>. <source><italic toggle="yes">Cellular and Molecular Immunology</italic></source>, (<issue>6</issue>), <fpage>621</fpage>&#x02013;<lpage>630</lpage>. <pub-id pub-id-type="doi">10.1038/s41423-020-0458-z</pub-id><pub-id pub-id-type="pmid">32415260</pub-id></mixed-citation></ref><ref id="CIT0060"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>N. C.</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>C. C. D.</given-names></name>, <name name-style="western"><surname>So</surname><given-names>R. T. Y.</given-names></name>, <name name-style="western"><surname>Lv</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Mok</surname><given-names>C. K. P.</given-names></name>, &#x00026; <name name-style="western"><surname>Wilson</surname><given-names>I. A.</given-names></name></person-group> (<year>2020</year>). <article-title>A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV</article-title>. <source>Science (New York, N.Y.)</source>, (<issue>6491</issue>), <fpage>630</fpage>&#x02013;<lpage>633</lpage>. <pub-id pub-id-type="doi">10.1126/science.abb7269</pub-id></mixed-citation></ref></ref-list></back></article>